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Aim of this thesis
In this thesis the growth characteristics of basal cell carcinoma (BCC), the most
common malignancy among Caucasians, is studied using molecular markers.
BCC is a non-melanoma type of skin cancer and accounts for approximately
80% of all skin malignancies and increasing incidence. The malignancy is
characterized by a slow growth and rare metastases, but occasionally the tumor
can infiltrate and cause severe damage to the underlying tissue. Since its
constantly increasing incidence and morbidity it becomes more and more
opportune to explore possible new non-invasive therapies based on basic
knowledge of BCC.
Since in general tumor growth can be achieved by either deregulating the cell
cycle, downregulation of cell loss, or both, this thesis concentrates on these
processes of cell proliferation and programmed cell death (apoptosis).
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Introduction
Basal cell carcinoma (BCC), a non-melanoma type of skin cancer, also called
basalioma, basal cell epithelioma, rodent ulcer and Jacobs' ulcer, was first
described in 1824' and is the most common cancer amongst Caucasians^. BCC
accounts for approximately 75% of all skin cancers. Mortality rates are relatively
low^, but BCC may occasionally grow aggressively causing extensive tissue
destruction*. Its ability to metastasize is low (< 0.1%)*. Metastasis to lymph
nodes, lung, bone and liver has been described '.
BCCs can be subdivided according to their differences in histological
appearance"^. The major histological patterns comprise nodular, micronodular,
superficial and morpheaform BCC. The nodular type is characterized by a
rounded mass of neoplastic cells with well-defined peripheral contours and
peripheral palisading is well developed. The superficial type is defined by one or
more tumor foci that extend from epidermis into the papillary dermis. Peripheral
palisading occurs and the peripheral contours are smooth. The micronodular
subtype is defined as small nodules and usually peripheral palisading is
present. The morpheaform subtype demonstrates tumor islands of varying size
with irregular outline and spiking configuration. Peripheral palisading is poorly
developed. Mixed types of these histological patterns may occur, with the
nodular-micronodular combination being the most common'". Furthermore,
BCC with more nodular type in the center of the malignancy and morpheaform
type at the periphery can occur. Finally, an adenoid pattern of BCC is seen in 1-
7% of the tumors and is mainly associated with the nodular type BCC". Nodular
(-60%) and superficial (-25%) BCCs are often considered as non-aggressive
subtypes, whereas morpheaform (-2%) and micronodular (-15%) BCCs are
often referred to as aggressive subtypes, and are associated with a higher risk
of recurrence'*.
Risk factors
The risk for development of BCC is associated with several patient dependent,
but also environmental factors.
- Environmental risk factors
BCCs generally occur on sun-exposed areas of the body" and high-risk
patients are often fair-skinned with a history of burning, not tanning, when
exposed to strong sunlight'*. Male gender, older age and number of previous
second-degree sunburns are also factors indicating a higher risk for
development of BCC'^. Corona et al.'^ showed in 2001 that there is a significant
association between BCC development and recreational sun exposure during
childhood and adolescence, as well as a strong relation with family history of
skin cancer. Patients with a BCC located on the trunk are at increased risk of
developing multiple BCCs, and these tumors develop at a faster rate than BCCs
located elsewhere on the body". Grossman et al.'® showed that there is a
correlation between UV-B exposure and development of skin cancer. However,
the significant number of BCCs arising on non-sun-exposed areas of the body
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suggests that other risk factors may play a role in the development of BCC^.
Diepgen et al.^° found that chemical carcinogens such as arsenic, coal tar
products and psoralens as well as ionizing radiation increase the risk of non-
melanoma skin cancer. Combination of UV irradiation and arsenic exposure
lead to an impaired process of nucleotide excision repair^. Excessive exposure
to psoralen during UVA-treatment in psoriasis patients also results in an
increased risk for BCC^. Prior non-diagnostic X-ray treatment for skin
conditions also enhanced the risk for BCC^. Furthermore, several authors
demonstrated an association between infection with the oncogenic types of
human papilloma virus (HPV) and development of BCC^"^, while Harwood et
a l .^ showed that HPV could abrogate UV-induced apoptosis. Furthermore, HPV
DNA was detected in BCC patients by Barr et a l . " and Weinstock et a l . " ,
suggesting HPV infection as a risk factor for developing BCC. With respect to
the relation between smoking and skin cancer development, De Hertog et a l . "
showed an association with squamous cell carcinoma but not BCC, while Boyd
et al .^ recently proved that an association exists between smoking and BCC in
young women. Furthermore, exposure to fiberglass dust and dry cleaning
agents also enhance the risk for BCC development^.
- GST Polymorphism
Genes that mediate detoxification processes, including individual responses to
UV irradiation by protecting from oxidative stress, are likely candidates for
susceptibility genes for BCC^. For example, glutathione S-transferase (GST)
enzymes are part of the cells' defense mechanism against numerous harmful
chemicals produced endogenously and in the environment^. UV irradiation
causes oxidative stress in the skin, which leads to lipid peroxidation and DNA
hydroperoxide formation'". GST is responsible for the disposal of these
potential mutagens^. Cytosolic GST activity in mammalian tissues is due to the
presence of multiple GST isozymes, which can be assigned to five classes e.g.
a, n, 7i, a and 0^. In human skin, GST activity can be found predominantly in
sebaceous glands and in the outer root sheath of hair follicles, the 7r-class of
GST being the predominant isozyme^. GST-TI has been suggested to be an
oncofetal protein that is re-expressed during carcinogenesis .^ A significant
increase in skin tumorigenesis is observed in mice lacking 7i-class GST^. In
humans, GST-TI is mainly expressed in malignant melanomas^, whereas BCCs
show only a weak expression of the protein^. Several polymorphisms in GST
family members exist"^* and have been associated with impaired
detoxification, thus influencing the risk for several cancers, including non-
melanoma skin cancer*°"\ A GSTT1 null genotype is associated with high UV
sensitivity^, and GSTM1 null genotype also predisposes for BCC due to its role
in defense against UV-induced oxidative stress^'". Polymorphism of GSTM3
was also shown to increase risk for BCC"*. Another genetic factor involved in
detoxification of photosensitizing agents, and thus involved in BCC
carcinogenesis is polymorphism of CYP2D6 (the gene encoding for cytochrome
P450), which is correlated with increased number of BCC . Furthermore,
CYP2D6 EM is associated with a multiple presentation phenotype of * ^
and these patients are also at higher risk for developing BCC"'.
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- Hereditary predisposition
In rare cases individuals can show an inherited predisposition for BCC. In 1973,
Milstone and Helwig*® noted that patients with Xeroderma Pigmentosum (XP), a
group of rare autosomal recessive disorders characterized by severe
photosensitivity due to various defects in the DNA repair of UV-induced lesions,
are prone to develop cutaneous cancers, mostly squamous cell carcinoma
(SCC) but also BCC*^ \ There are several variants of the disease, all caused
by a different genetic defect in nucleotide excision repair (NER), global genome
repair, transcription coupled repair or combinations thereof. Some of the genes
involved are essential components of the TFIIH transcription complex; their
absence is associated not only with UV sensitivity but also with sometimes
severe neurological defects and growth retardation (as in de Sanctis-
Cacchione)". Interestingly, at least two types of XP are caused by defects in
DNA helicases that are involved in NER and in transcription. Werner and Bloom
syndromes are hereditary skin cancer disorders that are associated with
helicase defects but, curiously, not with the development of basal cell
carcinomas"^. Rothmund-Thomsen syndrome, that in some cases is caused
by defects in a DNA helicase, does predispose to BCC^. The reason for this
difference is poorly understood. The expression patterns of helicases may play
a role but it is not clear why helicases should be tissue-specific. Chromosomal
breakage disorders such as ataxia teleangiectasia and Nijmegen Breakage
Syndrome do not predispose to BCC. Neither does Li-Fraumeni syndrome,
which is caused by germline mutations in the p53 gene, or dyskeratosis
congenital, a disorder associated with failure to maintain telomeres. Why these
forms of genomic instability do not seem to be causally related to BCC is
subject to speculation.
Moreover, patients with the nevoid BCC syndrome (NBCCS) or Gorlin
syndrome^, also show a rapid development of numerous tumors at young age.
Whereas XP is an autosomal recessive disorder, NBCCS is an autosomal
dominant disorder". A human homologue to the Drosophila segment polarity
gene patched, PTCH is mutated in NBCCS patients, suggesting a contribution
to the tumorigenesis^ ^. Since NBCCS patients normally inherit one mutated
copy of the PTCH gene, tumors are likely to arise after inactivation of the
remaining allele^°. Haplo-insufficiency of the PTCH gene is probably
responsible for the dysmorphisms. XP patients and sporadic BCCs may also
show mutations in the PTCH gene^"". The PTCH gene product is involved in
the so-called Sonic Hedgehog-signaling pathway, which is involved in
embryonic development^. Sonic hedgehog (shh) is expressed in the Hensen
node, the floor plate of the neural tube, the early gut endoderm, the posterior
limb buds and throughout the notochord, and encodes a signal responsible for
patterning the early embryo"^. At the cell surface, patched and smoothened
form a receptor complex for sonic hedgehog, which is a secreted molecule that
influences the differentiation of a variety of tissues such as brain, spinal cord,
limbs and axial skeleton®®. When sonic hedgehog binds to patched, it releases
smoothened, a transmembrane signaling protein, which is inhibited by binding
to patched protein^. High frequency of mutations in smoothened and patched in
BCCs, resulting in continuous activation of target genes, indicates that a
disturbed hedgehog pathway, resulting in excessive signaling, may be an
important carcinogenic route °. UV irradiation enhances BCC development in
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PTCH mutated mice^. Of the sporadic BCCs 20% show smoothened
mutations^ and 30-40% patched mutations'". In XP patients, the majority
(-80%) of PTCH mutations are UV-induced", more frequently than in sporadic
BCCs , where UV-signature mutations are seen in less than 50%™. PTCH2,
which is 57% identical to PTCH1, also serves as a receptor for hedgehog and
related factors^. Mutations occur in sporadic BCC^, and it has been shown that
when PTCH1 is mutated, PTCH2 mRNA is upregulated".
Finally, Rombo and Bazex syndromes are known to predispose to BCC. Both
are characterized by the presence of numerous small cysts in the face chest, as
well as by hypotrichosis. The cysts contain vellus hairs ^™. Rombo syndrome is
distinguished by striking degeneration of elastic fibrils in sunlight-exposed areas
causing dramatic skin alterations called atrophoderma vermiculatum" ™. In
Bazex syndrome, so-called ice-pick scars are seen on the backs of the hands.
This disorder is X-linked and has been mapped to Xq24-27. Rombo syndrome
is probably autosomal dominant, but elsewhise very similar to Bazex.
- Genetic changes
The most common genetic aberrations in human skin cancers are found at the
level of the p53 gene, which mediates cell cycle arrest after DNA damage".
The p53 gene encodes a phospho-protein that is involved in cell cycle control®".
In response to cellular stress, for example DNA damage, p53 is activated
through phosphorylation^ ®^ . Mdm2 can associate with p53 and regulates its
level and activity depending on the phosphorylation status of p53. When
dephosphorylated, p53 can bind to mdm2 and is then being degraded through
the ubiquitin-proteosome pathway"®''. In response to DNA damage, p53 is
phosphorylated and becomes detached form mdm2, resulting in stabilization
and activation of target genes regulated by p53® .^ The response to DNA
damage is either growth arrest, senescence or apoptosis®®. The relative cellular
content of p53 determines the response following DNA damage; when the
content is low to moderate, cells will go into cell cycle arrest to allow DNA
repair, but when p53 levels are high, cells will progress to apoptosis®^. P53 is
capable of stimulating pro-apoptotic Bax expression®®®^ (see also below). In
normal skin, wild type (WT) p53 is not detectable but appears within 2 hours
after UV irradiation, with peak levels at 24 hours after irradiation and again
undetectable levels at 36 hours after irradiation^. Mutant p53 can accumulate in
cells and p53 mutations have been detected in about half of all BCCs®"". It was
furthermore proven that histologically proven aggressive BCCs are significantly
associated with increased p53 expression, most probably representing the
mutated form. It is, however, strikingly that patients suffering from Li-Fraumeni
syndrome do not show increased incidence of BCC. In BCC patients, a study
comparing sunscreen users and non-users, it was shown that sunscreen users
showed a significantly lower level of p53 mutations in their BCCs than non-
users93. Mutation-hotspots have been identified, with two-third of the mutations
occurring at nine different sites^*. Inactivation of p53 occurs predominantly by
point mutation of one allele followed by loss of the remaining wild type allele .
The p53 gene shows UV-signature mutations i.e. predominantly C(C) -> T(T)
conversions^ ^ . In 33% of Korean BCC patients p53 mutations were detected®
and up to 50% of the Caucasian BCC patients showed this mutation^ ^ , thus
suggesting that different ethnic factors play a role in BCC carcinogenesis.
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Although at the moment no explanation at the molecular level is available for
this finding, polymorphisms in genes may be related to this phenomenon, as for
example the MC1R gene, coding for the receptor of melanocortin 1 and
involved in the regulation of pigmentation^. Polymorphism in this gene is
associated with squamous cell carcinoma or melanoma in the Irish and Scottish
population^ ^ .
P63, a p53 homologue, encodes multiple products and is restricted to cells with
high proliferate potential and absent from cells undergoing terminal
differentiation™. P63 has a nucleoplasmic distribution pattern in the basal
compartment of stratified epithelia such as skin, tonsil, bladder and certain
subpopulations of basal cells in prostate, breast, uterine cervix and bronchi'"'"
"". P63 deficient mice have striking developmental defects such as absence or
truncation of limbs, absence of hair follicles, teeth and mammary glands, and
the skin lacks stratification and differentiation"*. This indicates that p63 is
essential for several aspects of differentiation during embryogenesis. Several
isoforms of p63 can bind to p53 consensus-sequences and activate p53 target-
genes. Isoform TAp63y is capable of inducing cell cycle arrest and apoptosis'°^.
The AN isoforms, lacking the N-terminus, are unable to induce transcription,
and have an anti-apoptotic effect by rendering p53 and TA isoforms inactive.
P63 is only rarely mutated"**. It was furthermore shown that p63 functions not
only as a stem cell marker of keratinocytes"" but it also suggested that it
maintains the stem cell phenotype'°®. In consistency with its basal cell
localization in normal epidermis, BCC cells express p63'°"*'"^. It was shown,
that aberrant expression of p63 altered the UVB-induced apoptotic pathway
suggesting that downregulation of this protein in response to UV irradiation is
important in epidermal apoptosis"°.
- Immunosuppression
Organ transplant recipients are considered to be at greater risk for development
of malignancies because of the prolonged, often life long, immunosuppression
therapy'""'"''. Skin cancer is the most common malignancy occurring in the
setting of solid-organ transplantation and immunosuppression, and its incidence
increases substantially with extended survival after transplantation""*.
Surprisingly, squamous cell carcinoma (SCC) occurs more frequently in
transplant patients"^, whereas in the general population BCC occurs 3-6 times
more frequent than SCC"®. It was shown in Australian heart transplant
recipients that the number of skin cancers is significantly correlated with both
age at transplantation and duration of follow-up . In Europe, 40% of the renal
transplant recipients develop skin cancer within 20 years after grafting"®. Heart
transplant recipients are at higher risk than kidney transplant recipients most
probably due to the fact that they receive higher doses of immunosuppression
agents' ,^ but it cannot be excluded that the different types of
immunosuppressive agents have different effects in this respect.
People suffering from AIDS also have shown an elevated risk for the
development of BCC™ and HIV patients with BCC show more frequently blue
eyes, blond hair, family history and extensive prior sun exposure^'.
The major histocompatibility complex (MHC) genes code for membrane proteins
that play an important role in controlling immune responses'^. There are two
classes of genes, Class I (HLA-A, -B, -C) and Class II (HLA-DR, -DQ, DP),
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which play a role in host defense against development and spread of tumors'".
For example, loss of Class I antigens is related to tumor progression in
melanomas^*. Furthermore, abnormalities in cell-mediated immunity have been
reported in patients with multiple BCCs^. Whereas normal skin shows high
levels of Class I molecules, BCC shows either complete absence or
heterogeneous expression^. All Class I negative tumors were histologically
proven aggressive, whereas all non-aggressive BCCs were class I positive. The
low levels or absence of expression of Class I antigens may result in escape
from recognition by cytotoxic T cells, which then facilitates tumor growth^.
Evidence for the involvement of HLA-genes in the development of skin cancer
was provided by Bouwes Bavinck et al.™ These authors showed that the
presence of HLA-DR7 and a decrease of HLA-DR4 are significantly associated
with BCC. This corroborates the previous finding of Rompel et al. ^ that HLA-
DR4 is decreased in BCC, especially in patients with multiple BCCs located on
the trunk"°. The authors suggested a protective role for HLA-DR4 against
development of BCC. HLA-DR1 is weakly associated with the development of
multiple BCCs at an early age^ \ Furthermore, Bouwes Bavinck et al. presented
two studies showing a correlation between HLA-A11 expression and skin
cancer in immunosuppressed renal transplant recipients^ ^ . One of these
studies showed that HLA-A11 was associated with resistance to skin cancer in
renal transplant recipients^, while another study, in Australia, showed that
renal transplant recipients with HLA-A11 had an increased risk for developing
skin cancer"^. This apparent discrepancy may be the result of different genetic
background and differential environmental factors.
Although human papilloma viruses (HPV) has been associated strongly with
malignant progression of warts to SCC and with epidermodysplasia
verruciformis^"', different oncogenic subtypes of the virus were found in 60% of
BCCs from immunosuppressed patients in contrast to 36% of BCCs from non-
immunosuppressed patients, suggesting that these viruses may be involved in
the development of BCC^ . In renal transplant recipients with skin cancer HPV
5/8 DNA could be detected", and Weinstock et a l .^ suggested
immunosuppression to be a factor in BCC carcinogenesis by affecting HPV
infection.
Precursor cells
Several cell types have been suggested to be the precursor cells or stem cells
for BCC, i.e. interfollicular basal cells, basal keratinocytes from hair follicles or
sebaceous gland cells^"^®. In general stem cells have a relatively
undifferentiated and slow cycling phenotype, but can be stimulated to proliferate
and give rise to transient amplifying cells which have a limited proliferate
potential'^. Stem cells may be the target of carcinogens and as such play an
important role in tumorigenesis. For example, one observation that suggests
that stem cells are the most likely cells of origin for human skin cancer, is the
fact that sunlight exposure in childhood may contribute to tumors many decades
later^"°. As suggested by Taylor et al.™' the ultimate source of stem cells in the
skin is the hair follicle. These stem cells are most likely located in the bulge
18
region of the outer root sheath (ORS)'"^. As a result, hair follicles play a
potentially important role in skin homeostasis, wound healing and
tumorigenesis . Chemically induced BCCs in rats arise from hair follicles^,
while in humans, BCCs can apparently arise from both follicular and
interfollicular epidermis'^. Histologically, BCCs may resemble hair follicles",
and may show characteristics from both bulge region stem cells and transient
amplifying cells''*''. In particular, a small fraction of BCC may histologically
resemble trichoepithelioma, a benign hair follicle tumor'^. Especially the
suprabullar region of the ORS of the hair follicle shows an almost identical
immunohistochemical p r o f i l e ^ ^ suggesting a role for the lower ORS in the
generation of BCC. The hair follicle hypothesis is furthermore supported by the
fact that when a carcinogen is added in anagen-phase, in which the hair follicle
bulge region cells undergo transient amplification, BCCs are generated more
frequently^. Furthermore, BCCs seldomly occur on non-hairy skin"*'*. Support
for the hair follicle hypothesis can be found in the expression of the basal cell
adhesion molecule B-CAM in normal and diseased skin^®. The fact that this cell
surface protein is preferably expressed in suprabasal cell layers and the outer
root sheath of the hair follicle, and also shows high levels of expression in
BCCs, suggests BCC originating from hair follicles rather than from basal
keratinocytes, which are negative for B-CAM in normal skin. BCC However,
based on the lack of cytokeratin (CK) 15 expression in the tumor cells, BCCs do
not differentiate towards hair bulge cells'^.
In support of the interfollicular origin of BCC Howell et al.^° reported the tiny
pits in the epidermis of palms and soles characteristic for Gorlin syndrome ^
(also called nevoid basal cell carcinoma syndrome) occasionally show basaloid
budding into the dermis, and have therefore been suggested to resemble tiny
BCCs.
Carcinogenesis
Tumor formation results from a disruption of the normal balance between cell
proliferation and cell deatlV^. Three large categories of genes affect cellular
proliferation and survival, i.e. growth promoting oncogenes, tumor suppressor
genes and mutator or caretaker genes'^. The normal counterparts of
oncogenes, i.e. the proto-oncogenes, are crucial in regulating normal cell
cycling and division, differentiation and apoptosis'" '^. When these become
mutated or amplified they can overcome the normal restraints of cell
growth '^ '^ . Tumor suppressor genes negatively regulate cell growth or
promote cell death, and mutations or deletions of such genes have been
reported in various types of cancer^®"^°. Activation of proto-oncogenes and
inactivation of tumor-suppressor genes leads to an accumulation of genetic
abnormalities^. Defects in tumor suppressor genes appear to be more
common than defects in oncogenes^. Mutator or caretaker genes maintain the
genome integrity and when their function is altered, mutations can accumulate
more frequently " .
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• Proliferation versus differentiation in BCC
Proliferation indices vary greatly for the different subtypes of BCC, but in
general relatively high percentages of proliferating tumor cells are found^" ^ .
Based on immunohistochemical detection of the proliferation marker Ki-67 on
average 20% of the cells in BCC are prol i ferating^'"* '"""*. The proliferating
cell nuclear antigen (PCNA) is present in <10% of non-recurrent BCCs, while
recurrent BCCs show PCNA expression in >30% of the tumor cells^''™. In
nodular and superficial BCC the proliferative activity is mainly restricted to the
periphery of the tumor nests, whereas morphea-like tumors show a more
scattered pattern of proliferating c e l l s ^ ^ . An explanation for the zonal
distribution of proliferation-potent cells may be that tumor cells migrating
towards the center of the tumor nests become more differentiated, or have less
access to nutrients, resulting in lower proliferation potential*".
Markers for arrest of cell proliferation include the A-type lamins, also designated
Statins*". Nuclear lamins are intermediate filament proteins that form a network
at the nucleoplasmic site of the nuclear membrane and can be divided in two
sub-types, i.e. A-type lamins (lamin A, lamin AA10 and lamin C) and B-type
lamins (lamin B1 and lamin B2)*" " * . Aberrant expression patterns of lamins
have been described in cancer and it is thought that the nuclear matrix plays a
role in carcinogenesis*^ . In general, A-type lamin expression is correlated with
a non-proliferating, differentiated state of cells and tissues"^, and therefore
altered expression of A-type lamins can be expected in cancer. In BCC, it was
recently reported by Venables et al .*" , that the absence of lamin A correlated
with rapid growth, while the absence of lamin C correlated with slow growth of
this skin tumor. It was furthermore reported, that the expression of A- and B-
type lamins varies with differentiation in normal epidermis*™ and skin
tumors*™ "®. These authors support the idea that expression of A-type lamins,
but not B-type lamins is associated with the differentiation phenotype of the
tumors. Recently, Tilli et al.*®° reported four stages in BCC development based
on different patterns of A-type lamin expression. Stage 1 comprises lamin A
negative, Ki-67 positive BCCs, representing the origin of BCC, while stage 2
comprises lamin A positive, Ki-67 positive BCCs. As tumor growth slows down,
lamin C is first re-located to the nucleolus in stage 3 and in stage 4 lamin C
expression is largely diminished.
The fact that BCC show relatively high percentages of proliferating tumor cells
is not in line with the clinical finding that BCC is in general slow-growing*®*.
Therefore, the process of cell loss must be considered as an important factor in
the net growth of BCC. Already in 1972, Kerr*^ reported that a high apoptotic
rate in BCC might account for the paradoxically slow growth rate. Furthermore,
Mooney*" showed that indeed BCCs exhibit a high apoptotic rate as based on
in situ end labeling.
- Apoptosis in epidermis and BCC
Apoptosis, a form of programmed cell death, is characterized by cell shrinkage
and fragmentation*®*. Apoptosis is amongst others necessary for the correct
development of an embryo^, and to eliminate auto-reactive lymphocytes*®^.
Abnormal, unwanted or damaged cells are removed by apoptosis without the
involvement of the immune system, but through rapid phagocytosis of apoptotic
cells before lysis, which prevents inflammation*^. In this respect the process of
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programmed cell death can be clearly distinguished form accidental cell death,
i.e. necrosis.
During the different phases of apoptosis various sets of molecules act in an
orchestrated fashion. These include:
1. Death ligands and death receptors. The family of death receptors is
characterized by two to five copies of cysteine-rich extracellular repeats and a
death domain within the intracellular carboxy-terminus of the receptor (the death
domain)^®. When these death receptors are bound by ligand, apoptosis can be
induced. Fas is an example of a type I transmembrane receptor which mediates
apoptosis upon binding of the oligomerizing Fas Ligand (FasL)^. Fas is
expressed on several different cell types, while expression of FasL is restricted
to immune cells, including T and B lymphocytes, macrophages, and natural
killer ce l ls^°^ \ Ligation of FasL to Fas causes rapid death-inducing signaling
complex formation, which recruits and activates pro-caspase-8, thus triggering
the apoptotic caspase cascade (see below).
2. Bcl-2 protein family. Many studies concentrate on the Bcl-2 family of
apoptosis-regulating proteins ^ . Bcl-2 was first discovered in B-cell
lymphomas showing a t(14:18) translocation^, resulting in a Bcl-2-
Immunoglobulin-heavy chain fusion-gene^. This leads to the over-expression
of the anti-apoptotic Bcl-2 protein. The protein has been shown to suppress
apoptosis induced by various stimuli, such as depletion of IL-3 and IL-4 ^ ^ ,
p53-induced apoptosis^®, glucocorticoid treatment^, and c-myc induced
apoptosis^°°. Bcl-2 expression has been localized to long-lived (stem) cells in
self-renewing human tissues'! 53. The protein is associated with the membranes
of mitochondria, endoplasmatic reticulum and nucleus^, and bears 7
phosphorylation sites of which ser70 is critical for the apoptosis suppressing
function of Bcl-2^.
A large number of Bcl-2 related proteins^-^.203.204 ^ v e been isolated, which
can act either as apoptosis-inducing (e.g. Bax, Bcl-xs) or apoptosis-suppressing
agents (Bcl-xl). Heterodimerization between these family members determines
whether a cell will die or not to die*°"°®.
3. Caspases. The aspartate-specific cysteine protease (caspase) cascade
appears to be the main pathway for clearance of cellular constituents during the
execution phase of apoptosis^ . Several human caspases have been identified
that share similarities in amino acid sequence, structure and substrate
speci f ic i ty^^. Caspases show a high specificity for the conserved QACXG
sequence, resulting in the cleavage after aspartic acid (Asp) residues^". The
caspase family comprises apoptotic initiators (e.g. caspase-2, -8, -9 and -10)
and apoptotic executioners (e.g. caspase-3, -6 and - 7 f °®. Caspase-3 seems to
be responsible for the majority of apoptotic effects, and is supported by
caspase-6 and -7. These three executioner caspases are important in the
cleavage and degradation of several substrates, target-proteins that are
involved in RNA splicing, DNA repair, and scaffolding of the cytosol and the
nucleus. Upon induction of apoptosis, caspase-3 cleaves the inhibitor of the
caspase-activated DNAse, resulting in degradation of DNA into
oligonucleosomal fragments*" ^*. Lamin A is cleaved by caspase-6^"^, while
also cytoskeletal filaments such as cytokeratins are cleaved by caspase-6^.
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The externalization of phosphatidyl-serine at the cell membrane during
apoptosis is also caspase-dependent^. The nuclear matrix protein poly(ADP-
ribose) polymerase (PARP) is also proteolysed by caspases during
apoptosis^.
Inhibitors of apoptosis proteins (lAPs), which are constitutively present in
cells^®^, for example bind to and inhibit caspase-3 and -7 as well as pro-
caspase-9, but not capase-1, -6, -8 or-10.
When apoptosis occurs inappropriately it may cause degeneration of normal
tissue architecture or function. On the other hand, when apoptosis fails to occur
this can give rise to deregulation of tissue homeostasis, as a result of which
neoplasms can arise.
Apoptosis in the epidermis is a common phenomenon. In the morphogenesis of
human fetal skin and maintenance of adult epidermis apoptosis plays a pivotal
role^°. For example, the apoptosis machinery is activated during the normal
terminal differentiation process in keratinocytes^. In fetal skin, cells undergoing
apoptosis are present in several epidermal cell layers, whereas in neonatal
epidermis these are found in the terminally differentiating granular cell layer,
and in adult skin also the spinous cells show occasional apoptosis^".
Furthermore, apoptosis occurs upon excessive UV light exposure, resulting in
un-repairable DNA damage^. A significantly negative correlation between the
expression of either p53 or Bcl-2 with the development of BCC has been
described previously . Mutation of p53 or over-expression of Bcl-2 is sufficient
to enhance formation of BCC by suppressing ^ ^
Altered expression of Bcl-2 family member proteins in non-melanoma skin
cancer has been reported extensively before , suggesting that deregulation of
expression of these proteins may be a possible explanation of the indolent
growth-behavior of B C C ^ ^ " . Bcl-2 is in general homogeneously expressed in
£QQ168 228-230 ^,^j|g g|gQ f(-,g apoptosis-inducing Bax protein is expressed at
high levels^®"®. These data clearly show that a considerable proportion of cells
in BCC are in principle capable of undergoing apoptosis, corroborating the
earlier finding of Mooney^.
Another apoptosis inhibitor protein called survivin is expressed in 81% of BCC,
whereas it is not detected in normal skin, suggesting a contribution to the
progression of ^ \
Also Fas-mediated apoptosis may be important for skin homeostasis. Hill et
al ."* suggested that deregulation of Fas-FasL interactions may be central to the
development of skin cancer. In normal skin, Fas is expressed in cytoplasmic
membranes of the basal cell layer, while after sun exposure the expression of
Fas is upregulated in the entire epidermis. After further UV exposure, Fas
expression is again down regulated, resulting in a negative staining in BCCs"^.
BCCs express however strongly and diffusely FasL, providing evidence for an
escape from local immune surveillance by the induction of apoptosis in the
peripheral T lymphocytes"".
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Induction of apoptosis in therapy of BCC
Different surgical and non-surgical therapies are available for the treatment of
BCC"^. Medical history of the patient, age, tumor localization and size, physical
condition, histological outcomes and cosmetic aspects will eventually determine
the choice of therapy. Furthermore, Telfer et al. ^ published guidelines for the
management of BCC, presenting evidence-based guidance for treatment. In
spite of the fact that surgical excision is still the most prominent therapy used,
non-invasive therapies like photodynamic therapy (PDTf" or topical application
of 5-fluorouracil are currently becoming more and more interesting in
selective cases, especially because of the improved cosmetic outcome.
Many currently used anti-neoplastic agents exert their therapeutic effects
through the induction of apoptosis. Different cell types vary profoundly in their
susceptibility, suggesting the existence of distinct cellular thresholds for
apoptosis induction"^. For example, BCC cells over-expressing IL-6 are
resistant to UV irradiation and PDT-induced apoptosis^". Furthermore, it was
shown that de novo p53 synthesis or stabilization of p53 is essential to induce
apoptosis in BCC^\ Over-expression of the anti-apoptotic Bcl-2 has also been
linked to resistance of cancers to various chemotherapeutic drugs^.
In BCC Interferon (IFN)-a induces apoptosis and is thus effective in the
treatment^. Untreated BCC cells express FasL but not the receptor, but in IFN-
alpha-treated BCC patients the tumor cells express both FasL and receptor,
whereas the peritumoral infiltrate mainly consists of Fas-receptor-positive
cells^*. Upon IFN-a treatment the BCCs therefore most likely regress through
apoptosis.
Topical treatment of BCC with 5-fluorouracil (5-FU) has also been proven to be
very successful. Up to 90% of treated BCCs show regression when 5-FU is
applied in a phosphatidyl choline-based cream^ or when it is locally injected in
an epinephrine containing geP®. The regression of the tumors treated with 5-
FU is probably caused by enhancing apoptosis in the tumor
Recently, Nakaseko et a l . ^ reported that apoptosis is involved in regression of
the lesion after photodynamic therapy (PDT) in Actinic Keratosis. This therapy is
also used for treatment of BCC * , where tumor cells may also undergo
apoptosis.
Retinoids (vitamin A metabolites and analogs) have also been shown to have
suppressive effects on tumor promotion, and the mechanism appears to be
associated with modulation of growth, differentiation and apoptosis .^
Also more and more phytochemicals are being applied in cancer prevention and
therapy"". Recently, Levin and Maibach^ published an overview of alternative
drugs and treatments in dermatology. It was shown that by application of green
tea polyphenolic fractions reduced the UV-induced erythema, gave rise to a
decrease in sunburns and could also reduce UV-induced mutations in DNA"^.
Oral and topical application of black tea extracts also decreased photochemical
damage to the skin"^. Furthermore, in mice bearing skin tumors, tumor growth
was inhibited by 70% after treatment with black tea, which was established by
inhibition of proliferation and enhanced apoptosis"''. Ajoene, an organosulfur
compound of garlic"^, has been shown to induce apoptosis in human
promyeloleukemic cells"®. Recently, it was shown that ajoene can induce
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apoptosis in the human keratinocyte cell line HaCat and has a diminishing effect
on BCC in vivo by downregulating the expression of the apoptosis-suppressing
protein Bcl-2 (Tilli in press).
Based on the foregoing it is our firm believe that the development of future
therapies for BCC will be strongly influenced by attempts to specifically induce
apoptosis in these tumor cells.
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Summary
Background / Objectives
A considerable portion of the hair follicle remains attached to plucked hair and
can be used for follicle cell culture. In this study we have phenotyped these cells
in an attempt to identify the stem cell fraction. Reports in the literature have
indicated that this cell population may be positive for cytokeratin (CK) 19. Since
stem cells in general need to be protected from apoptosis, the presence of the
apoptosis suppressing Bcl-2 protein, together with the absence of the apoptosis
promoting Bax and the CK profile may, be used as an indicator of the stem cell
population in the hair follicle, and in cultures of hair follicle cells.
Methods
Hair follicles from skin biopsies and plucked hair were derived from the scalps
of healthy volunteers. Follicular cells were cultured from the plucked hairs.
These hair follicles, plucked hairs, and cultured cells were examined for their
CK profiles, which are indicative of the type of cell (basal/stem cells), and for
their status with respect to the proliferation marker Ki-67, Bax, and Bcl-2.
Results
We found co-expression for CK19 and Bcl-2, but not Bax in two distinct areas,
localized in the upper and lower third of the follicle from both skin biopsies and
plucked hairs, while proliferation markers were negative in these areas. CK19
and Bcl-2 were also co-expressed in combination in a fraction of the follicular
cell culture. The skin basal cell marker CK14 could be found throughout the
outer root sheath of the hair follicle from both skin biopsies and plucked hairs,
as well as in the follicular cell culture.
Conclusions
Thus, CK19 / Bcl-2-positive and Bax-negative cells can be obtained from cells
derived from plucked hair and are retained in cultures made from these cells. If
this phenotype represents follicular stem cells, our finding endorses the
assumption that stem cells are located in the bulge area of the hair follicle, as
we did not find them in or near the dermal papilla.
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Introduction
Although a considerable portion of the hair follicle is attached to plucked hair,
transplantation of a plucked hair does not result in normal hair growth', in
contrast to hair from micro-punch grafts^. This can be explained by the fact that
the structures of the hair follicle that are retained in the skin after the hair is
plucked, are necessary for normal hair growth. However, when outer root
sheath (ORS) cells derived from plucked hairs are cultured, they can develop
into a differentiated epidermis^, suitable for use in skin grafts". We therefore
speculated that the plucked hairs themselves might contain epidermal stem
cells.
When plucked hair is dissected, the various transverse sections have been
shown to exhibit different proliferative and differentiative characteristics^. It has
been suggested that adult human follicular stem cells from terminal hairs are
situated in the bulge area of the follicle. These cells have been suggested to
exhibit various specific biochemical properties. For example they have
epidermal growth factor (EGF) receptors, show alpha2beta1- and alfa3beta1-
integrin expression®, high levels of alpha6-integrins and low levels of the
proliferation marker 10G7^, and stain positively for platelet-derived growth factor
(PDGF)-A/PDGF-B ligand chains. They do not contain nectadrin, or heat-stable
antigen (CD24), a glycoprotein thought to be involved in cell-cell adhesion and
signaling, which is also expressed in the outer epithelial sheath of human hair
follicles and in glabrous epidermis^. However the CK apoptosis resistance
profiles seem to have become key indicators of a stem cell phenotype.
During development into a terminal hair, the CK profile of the follicular
keratinocyte changes. It has been proposed that CK19 is an indicator of the
stem cell population™'^. CK19 is present in immature epithelial progenitor
cells^, but in the hair follicle it is specific for follicular stem cells™ " . In adult hair
follicles, CK19 can be found in the outermost cells of the ORS at the isthmus
and in some cells of the lower ORS™. It is proposed that the actual follicular
stem cells are CK19-positive and lack connexin (Cx) 43, a specific
differentiation marker for a gap junction protein.
A balance between cell proliferation, differentiation and apoptosis is essential
for hair growth^ ^, while stem cells must be protected against apoptosis. This
protection is achieved by proteins such as Bcl-2, while Bax, a conserved
homologue that heterodimerizes with Bcl-2 promotes cell death". The
characteristics of the CK profile, in particular the expression of CK19, but also
CK5 and CK14 as basal cell markers", together with the expression of Bcl-2
and absence of Bax expression, may therefore be used as indicators of the
stem cells in the hair follicle.
The aim of this study was to localize the follicular stem cells in the hair follicle
from skin biopsies and to characterize them on the basis of their CK phenotype,
presence of Bcl-2, and absence of Bax. Furthermore, we wished to determine
whether these cells are present in plucked hair and preserved in cell cultures
derived therefrom.
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Materials and Methods
Skin biopsies
Five healthy volunteers, three males and two females between the ages of 28
and 53 years (mean age 37 years) donated skin biopsies.
Biopsies
Four 3-mm punch biopsies were obtained from the occipital area of the scalp
after local anaesthesia with lidocaine 2%. The tissue samples were immediately
frozen in liquid nitrogen and stored at -80°C until use. Samples were then cut
into 5-um thick sections in a vertical direction and carefully placed on Superfrost
plus slides (Menzel-Glaser, Germany).
Plucked hair
Plucked hairs were obtained by removing the hairs with a depilation forceps
from the occipital area of the scalp. Hair follicles in the anagen phase were
selected under a dissection microscope, and embedded in Tissue Tek (Sakura
Finetek Europe B.V., Zoeterwoude, The Netherlands), and directly cut into 5-um
sections as described above.
Cell cultures
Plucked hairs were placed in a Petridish with Defined Serum-Free Keratinocyte
Growth Medium (dSFK; Life Technologies B.V. Breda, The Netherlands). The
nonviable, keratinised part of the hair follicle was removed under a dissection
microscope. The hair follicles were subsequently put in a sterile culture disk and
incubated in dSFK containing 20U/ml dispase (Sigma-Aldrich Chemie BV,
Zwijndrecht, The Netherlands) for 30 minutes in a CO2 incubator at 37°C. After
this pre-incubation step, the hair follicles were transferred to a 24-well culture
disk containing dSFK with 500 (.ig/ml penicillin (Life Technologies B.V. Breda,
The Netherlands) and 0.25 ng/ml streptomycin (Life Technologies B.V. Breda,
The Netherlands), and placed for 14 days at 31°C in a humidified atmosphere
containing 5% CO2. The culture medium was carefully removed every three
days and replaced by fresh culture medium. The cells remained attached to the
hair follicles during this culture period. After 14 days the culture medium was
removed and replaced by a 0.5mg/ml trypsin, 0.2mg/ml EDTA (ethylene
diaminetetraacetic acid) solution (Life Technologies B.V. Breda, The
Netherlands), and incubated for 5 minutes at 37°C in this medium. After this
incubation period clusters of cells were released from the hair follicles. These
were harvested by centrifugation at 300 g at 4°C for 5 minutes in an Eppendorf
5804R Centrifuge (VWR International, The Netherlands). Subsequently the
trypsin/EDTA medium was removed and replaced by culture medium. Cytospins
were made from these cells in the Cytospin 3 (SHANDON, Zeist, The
Netherlands) by centrifugation at 600 rpm for 5 minutes.
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Table 1: Antibodies and their dilutions used in this study
Antibody
Basal cell
LL002
RCK107
RCK108
LP2K
Isotype
markers
mouse lgG3
mouse I g d
mouse I g d
mouse lgG2b
Proliferation markers
LL025
MIB-1
A0047
Apoptosis
N-19
124
PC66
mouse IgGi
mouse I g d
rabbit IgG
markers
rabbit IgG
mouse IgGi
rabbit IgG
Antigen
CK14
CK14
CK 19
CK19
CK 16
Ki-67
Ki-67
Bcl-2
Bcl-2
Bax
Dilution
UD
UD
1:5
UD
1:10
1:25
1:100
1:200
1:80
1:750
Source
Purkis et a l .^
Wetzeis et al.*°
Kwaspen et a l / "
Stasiak et al.**
Wetzeis et al.*°
Immuno Technology,
Marseille, France
DAKOA/S.GIostrup,
Denmark
Santa Cruz
Biotechnology Inc.,
Santa Cruz, CA, USA
DAKO A/S, Glostrup,
Denmark
Oncogene Research
Products, Cambridge,
MA, USA
Immunocytochemistry and antibodies
The sections and cytospins were dried at room temperature for at least 1 h,
fixed in acetone (at -20°C) and processed for immunohistochemical staining.
For the single immunostaining procedure, the slides were incubated overnight
at 4°C with the primary antibodies. All incubations were carried out in
phosphate-buffered saline (PBS) pH 7.4 at the appropriate dilution (table 1).
The following day the slides were washed with PBS and incubated at room
temperature for 30 min with the appropriate immunofluorescent-labeled
secondary antibody (table 1). After extensive washing, the slides were mounted
with a 4,6- diamidino-2-phenylindole (DAPI)-containing mounting agent (Vector
Laboratories Inc., Burlingame, CA, USA) and stored at -20°C.
For double-immunostaining, the primary antibodies were selected on the basis
of their isotypes, or a combination of monoclonal (mouse source) and polyclonal
(rabbit source) antibody was applied as described in table 1. The first primary
antibody was incubated overnight at 4°C and the next day, after washing, the
second primary antibody was incubated at room temperature for 2 h. After
extensive washing in PBS, a mix of the appropriate secondary antibodies was
applied and incubated for 30 min at room temperature. Subsequently the slides
were washed in PBS, mounted as described above, and stored at -20°C.
Amplification of signal was achieved by incubation with biotinylated goat-anti-
rabbit (BIO-GAR) or biotinylated goat-anti-mouse (BIO-GAM) and Avidin-Biotin
complex (Vectastain ABC kit, Vector Laboratories Inc., Burlingame, CA, USA)
after incubation with the primary antibody. Detection of peroxidase activity and
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simultaneous signal amplification was achieved by incubation with
tetramethylrhodamine isothiocyanate (TRITC)-labeled tyramide or fluorescein
isothiocyanate (FITC)-labeled tyramide ®.
Results
HE staining of skin biopsies and plucked hair
Comparison of the hair follicles derived from skin biopsies and from plucked
hairs using light microscopy revealed that most of the epithelial structures from
the hair follicle remain attached to the plucked hair (Fig.1).
Figure 1: H&E
staining of
plucked hair.
Most epithelial
structures from
the follicle
remain
attached to the
plucked hair.
Adjacent to the
longitudinal
section of the
plucked hair
(x10)the
respective
areas are
shown at a
higher
magnification
(x40).
Basal cell makers: CK14 and CK19
Cells positive for the basal cell markers CK14 (RCK107, LL002) were found in
the basal cells throughout the whole length of the ORS of the hair follicle and in
the basal cell layer of stratified epithelium of the epidermis, both in the skin
biopsy samples and in the plucked hairs.
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Figure 2: A) Details (x40) from a
longitudinally sectioned hair follicle from skin
biopsies double stained for CK19 in red and
Bcl-2 in green. Two areas were found to be
positive for both markers; i.e. the upper third
(A) and lower third (B) of the hair follicle.
Figure 3: A) Bcl-2 and
B) CK19 staining of
cells, derived from
plucked hair and
cultured for 14 days.
Next to cells that are
positive for both
markers (arrows),
some cells are only
Bcl-2 or CK19 positive.
Figure 4: Details (x40)
from a longitudinally
sectioned dermal papilla
(A) and hair follicle (B)
from skin biopsies double
stained for Bax in red and
Bcl-2 in green.
Figure 5:
Longitudinally
sectioned plucked
hair (x10) double
stained for Bcl-2 in
green and Ki-67 in
red. Higher
magnifications (x40)
of areas found to be
positive for both
markers are shown
next to the
respective areas of
the hair follicle.
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In the hair follicles from the skin biopsy, the basal keratinocyte cell marker CK19
(RCK108, LP2K) was found in the most peripheral cell layer in two distinct
areas in the upper (Fig 2A) and lower third (Fig 2B) of the ORS, but not in the
epidermis. In the plucked hair, the same regions were found to be positive for
CK19 (Results not shown). In follicular cell cultures approximately one fifth of
the cells were CK19 positive. These CK19-positive cells were mostly found as
cell clusters, as shown in Fig. 3B.
A complete overlap of CK19 (RCK108) and CK14 (LL002) was found in the
biopsy samples and in plucked hair, and in approximately 40% of the cultured
cells (not shown).
(Anti-) Apoptosis markers: Bcl-2 and Bax
Bcl-2 (N-19) positive cells were found in the outermost cell layer throughout the
whole length of the ORS of the hair follicle from skin biopsies, as well as in the
basal layer of the epidermis. We also found Bcl-2 positive cells in the most
peripheral cell layer of the whole length of the ORS of the plucked hairs. Bcl-2
positive cells were not found in the dermal papilla. Double staining for CK19
(LP2K) and Bcl-2 (N-19) revealed that CK19-positive cells were also positive for
Bcl-2. However, not all Bcl-2-positive cells were positive for CK19 (Fig. 2A, B).
In the follicular cell cultures subjected to double-staining techniques, some cells
stained positive for both Bcl-2 and CK19, while others were positive for either
Bcl-2 or CK19 (Fig.3A,B). Figure 3B shows a typical cluster of CK19 positive
cells, found in the cytospins of the cell cultures.
Bax (PC66)-positive cells were present in the internal part of the ORS both in
the hair follicles from skin biopsies and in the plucked hair. Bax-positive cells
were found in the dermal papilla in the hair follicles from skin biopsies (Fig. 4A)
and in the most proximal part of the plucked hair (Fig. 4B). Almost no overlap
(<5%) between Bcl-2 (124) and Bax (PC66)-positive cells was found in either
sample. However, in follicular cell culture there was more overlap (30-40%)
between Bcl-2- and Bax-positive cells (results not shown).
(Hyper-) Proliferation markers CK16 and Ki-67
CK16 (LL025)-positive cells were found in the distal internal part of the ORS of
the hair follicles, both from skin biopsies and plucked hairs. No CK16 staining
was observed in the most proximal part of the hair follicles, either from skin
biopsies or plucked hairs. CK16-positive cells were found in the internal part of
the ORS, in contrast to CK19-positive cells whose position was more peripheral.
There was no overlap between CK16 and CK19 staining in the hair follicles from
skin biopsies, plucked hairs or follicular cell culture. There was an overlap in the
immunostaining patterns of CK14 (LL002) and CK16 (LL025) in the ORS of the
hair follicles from skin biopsies and in the plucked hair, where CK16-positive
cells were located. In follicular cell culture there was virtually a total overlap
between CK14- and CK16-positive cells (not shown).
Ki-67-positive cells were sporadically found (Fig 5). Their location tends to be
more toward the internal part of the ORS, although some were found near the
external part of the ORS near the CK19-positive cells. Ki-67-positive cells were
also found in the dermal papilla. Less than 1% of Ki-67-positive cells were found
in follicular cell culture.
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Discussion
Although plucked hair seems to contain all of the epithelial structures that are
present in the hair follicle derived from skin biopsies, the transplantation of
plucked hair does not result in normal hair growth, in contrast to hair-containing
punch grafts \ The fact that the structures of the hair follicle remaining in the
skin can produce a normal hair, suggests that follicular stem cells are retained
in the skin. However, when hair follicle preparations derived from skin biopsies
are compared with preparations from plucked hair under a light microscope, it
can be seen that the majority of the epithelial structures from the hair follicle
remains attached to the plucked hair. The question thus arises whether or not
follicular stem cells are extracted with the plucked hair, and whether the stromal
tissue surrounding these epithelial structures is necessary for induction of hair
growth. This follicular connective tissue has specific biochemical characteristics,
such as the presence of PDGF-alpha and PDGF-beta receptors and
versican^^°, that seem to play a role in (embryonic) hair follicle development
and cycling.
We based our search for the follicular stem cell population in plucked hair and
cultures thereof on stem cell characteristics proposed in the recent literature^,
i.e. the expression of CK19 and Bcl-2, in combination with the absence (or low
levels) of Bax expression^, and an extremely low proliferation frequency^. In
1996, Michel et a l . " suggested that CK19-positive cells in hair follicles
represent stem cells. Furthermore, stem cells in general express Bcl -2^" . In
normal skin, Bcl-2 is only expressed by a limited population of cells in the basal
compartment, which can be regarded as the stem cell compartment^.
An important finding in this study is that phenotypical characteristics of the hair
follicle from skin biopsies are preserved in plucked hair, including the
expression of CK19^° and Bcl-2 ^  in cells from two areas of the upper and lower
third of the follicle. Positivity for CK19 and Bcl-2 corresponds to infrequent cell
division in these areas, as concluded from the absence of Ki-67 staining. The
fact that these cells are positive for Bcl-2 and CK 19, but Ki-67 and Bax
negative, is a strong indication that they represent stem cells in the hair follicle.
Our results also indicate that transient amplifying cells in the epidermis, which
are expected to be Ki-67 positive, are largely Bcl-2 negative. All the markers
found in the hair follicle from skin biopsies were also preserved in the follicular
cell culture derived from plucked hair, including CK19 and Bcl-2, and the basal
cell marker CK14. We therefore conclude that viable follicular stem cells can be
obtained from plucked hairs. The low frequency of Ki-67 positive cells indicates
that differentiation may have occurred in these cell cultures, which can also be
concluded from the CK10 staining in a proportion of the cells (unpublished
observation).
The observation that two distinct areas in the hair follicle from skin biopsies are
positive for CK19 was also found by Commo et a l . " . The fact that these areas
are also Bcl-2 positive, and Bax negative, is a strong indication for two stem-cell
sites. The question therefore arises whether or not both areas are necessary for
hair growth induction. In humans, Kim et a l . " found that the proximal part of the
hair follicle cannot regenerate into a differentiated hair follicle, but the distal part
of the follicle can, eventually resulting in a fully developed hair follicle^.
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Reynolds et a l .^ found that, although the dermal papillae of humans cannot
induce new hair growth, the sheath of the lower part of the hair follicle can.
These apparently contradictory results indicate that both proximal and distal
areas of the hair follicle can induce hair growth, which agrees with our finding of
two stem cell locations.
In addition to these two areas, the dermal papilla has also been ascribed a key
role in hair growth. In rats, cultured dermal papilla cells from whisker hairs can
generate a fully differentiated hair follicle^, suggesting that follicular stem cells
are located in or near the dermal papilla. The cells in this region that are held
responsible for hair growth are the germ cells. Recently a hypothesis of hair
cycling was proposed that involves participation of these germ cells next to the
bulge region stem cells'". In our study, the dermal papilla in the hair follicle of
the skin biopsy did not contain Bcl-2. In contrast other studies have found Bcl-2
positivity in the dermal papil la^*, but the tissues used in these studies were
either embryonic or derived from non-melanoma skin cancers. The apparent
discrepancy in findings could be due to the fact that, although Bcl-2 is normally
found in the basal compartment of normal skin, there is an expansion of this
Bcl-2 positive cell population under pathological circumstances such as basal
cell carcinoma (BCCF "•
In our study we found that the dermal papilla is positive for Ki-67 and Bax. This
immunophenotype, in combination with the Bcl-2 negativity, is not in agreement
with the characteristic definition of a follicular stem cell population, but rather
supports the findings of others that follicular stem cells are not present in the
dermal papilla^ ^. However, taken all these findings together suggests that hair
growth involves the co-operation of various stem cell regions.
The inability to successfully transplant plucked hairs containing the two stem
cell regions may be due to the lack of appropriate conditions in the stromal
tissue of the recipient areas. A similar lack of growth has been observed in case
of transplanted epithelial structures derived from BCC which could not be
induced to proliferate without the transplantation of additional stromal cells^.
This comparison is justifiable since BCC are most likely derived from follicular
germinative c e l l s ^ . Another indication of the importance of stromal cells for
the growth of keratinocytes is the observation that keratinocyte cultures may
require a fibroblast feeder layer*.
Unsuccessful regeneration after implantation of plucked hairs may also be
caused by the inflammatory response of the receptor area to the plucked hairs,
which may result in the destruction of the follicular stem cells. The connective
tissue surrounding these epithelial structures in micro-punch grafts may be
crucial for protection against inflammation, and thus a successful
transplantation. Therefore, the importance of the connective tissue of the hair
follicle cannot be ignored^®. Follow-up studies will focus on the role of
components of the connective tissue and the extracellular matrix surrounding
the epithelial portion of the hair follicle.
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Abstract
Background
To understand the typical growth behavior of basal cell carcinoma (BCC) we
searched for the correlation between proliferation and apoptosis and
progression of BCC.
Methods
Expression of Bcl-2, Bax, and Ki-67 was immunohistochemically investigated in
both normal skin and BCC cells, as well as in the epidermis overlying BCC.
Results
The results showed that in normal epidermis, Bcl-2 was homogeneously
expressed in the basal cell compartment, whereas Ki-67 expression was largely
restricted to the parabasal layer, the layer just above the basal cell layer, and
exhibited a more scattered staining pattern. Bax was occasionally expressed in
the basal layer and widely in the suprabasal compartment. Strikingly, the
apparently normal epidermis overlying BCC showed an increased Bcl-2
staining. In BCC, cells stained homogeneously for Bcl-2, whereas Bax and Ki-
67 showed scattered staining patterns. Simultaneous expression was seen for
Bcl-2 and Bax in 80±7% of the tumor cells, and co-expression of Bcl-2 and Ki-
67 in 20±7% of the tumor cells. The cells expressing Bcl-2 and Ki-67, but
lacking expression of Bax, the progressive fraction, comprised on average
7±3% of the tumor cell population.
Conclusion
These results suggest that this small progressive fraction of tumor cells, in
combination with the relatively high percentage of cells still prone to apoptosis,
can explain the indolent growth behavior of BCC.
Keywords: basal cell carcinoma, proliferation, apoptosis, Bax, Bcl-2, Ki-67
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Introduction
Basal cell carcinoma (BCC), the most common malignancy in Caucasians, is a
non-melanoma type of skin cancer arising predominantly in the face and neck. It
is a typically slowly growing tumor with a great diversity in histopathological
appearance . Although generally of indolent nature, occasionally the tumor can
become very aggressive and destructive, a clinical behavior that is mainly
related to the morpheaform, metatypical or micronodular phenotype\
In general, growth of a tumor is based on a derailment of cell proliferation^.
However, it has been shown in previous studies that the duration of a cell cycle
in BCC resembles that of keratinocytes of the generative compartment of
normal epidermis, approximately 217 hours''. This is in contrast with the clinical
observation that BCC is an extremely slowly growing tumor, which may take
months or even years to double in size*. It has therefore been suggested that
only a small percentage of all tumor cells is actively proliferating and it was
found that these cells are mainly located at the periphery of the tumor nests^.
In addition, an increase of the apoptotic potential of BCC cells may be another
explanation for this phenomenon.
Apoptosis is partly regulated by the balance between the expression of anti-
apoptotic protein Bcl-2 and the pro-apoptotic protein Bax (Bcl-2 associated x-
protein). The Bcl-2 gene was first discovered in B-cell-lymphomas showing a
t(14:18) translocating The resulting fusion gene yielded an over-expression of
the Bcl-2 protein®. This translocation is frequently found in various cancers and
it was shown by Reed ef a/® that the Bcl-2 protein could suppress apoptosis
induced by various stimuli. Bax was discovered in an immunoprecipitation
assay when it co-precipitated with Bcl-2. Although it exhibits a high degree of
homology with Bcl-2, this protein showed pro-apoptotic activity™. Over-
expression of Bax results in homodimerization and suppression of the
functionality of Bcl-2, followed by the induction of apoptosis. Over-expression of
Bcl-2, however, results in cell survival. It can thus be concluded that the relative
expression levels of these two proteins in part determine the fate of a cell™.
Since most tumor cells in BCC show expression of Bcl-2\ the expression level
of the Bax protein may determine whether a cell lives or dies.
The slow expansive growth of BCC must therefore be explained in the light of
the delicate balance between cell generation (proliferation) and cell loss
(apoptosis), which is responsible for the tissue homeostasis in multi-cellular
organisms, and becomes disturbed in tumor development.
The aim of this study was to determine and quantify the cell population in BCC
that is responsible for its expansion i.e. the tumor cells that are protected from
undergoing apoptosis (Bcl-2 positive, Bax negative) and are actively
proliferating (Ki-67 positive). It was found that this cell population comprises a
minor fraction of the tumor cells and is smaller than the cell fraction that can
potentially undergo apoptosis.
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Figure 1: Specificity testing of
the Bax and Bcl-2 antibodies
A. Polyclonal Bax antibody (Ab-
1) in normal skin. Note sporadic
expression in basal layer of the
epidermis and more extensive
expression in the suprabasal
layers.
B. Polyclonal Bax antibody (Ab-
1) pre-incubated with blocking
peptide: no staining present.
C. Polyclonal Bcl-2 antibody (N-
19) in BCC: epidermis and tumor
cells show expression of the Bcl-
2 protein.
D. Polyclonal Bcl-2 antibody (N-
19) pre-incubated with blocking
peptide: no staining present.
E. Monoclonal Bcl-2 antibody
(Clone 100) in normal skin:
basal layer positive, suprabasal
layers negative.
F. Polyclonal Bcl-2 antibody (N-
19) in normal skin: comparable
result as observed for the
monoclonal antibody.
G. Immunoblotting results with
the monoclonal (Clone 124, lane
a) and polyclonal antibody (N-
19, lanes b and c) against Bcl-2:
a single band is detected with
both antibodies at the expected
molecular weight of 29 kDa in
the MCF-7 and Jurkat cell lines.
H. Immunoblot with the
polyclonal Bax antibody (Ab-1):
one single band was detected at
the expected molecular weight
of 21 kDa in 3T3, HT29 and
HeLa cell lines.
The 40x objective was used for photography of images 1 A-F.
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parabasal cells (see arrows).
F. Bax (red) and Ki-67 (green): Increased number of cells
epidermis overlying a tumor as compared to normal epidermis.
The 40x objective was used for photography of images 2 A-F.
Figure 2: Proliferation- and
apoptosis markers in the epidermis
A. Bcl-2 (green) and Ki-67 (red): Bcl-
2 was found to be present in the
basal cell layer of the epidermis of
normal skin, whereas Ki-67 is mainly
restricted to the parabasal layer.
B. Bcl-2 (green) and Ki-67 (red):
There are some clear differences in
expression of Bcl-2 and Ki-67 in the
epidermis overlying BCC as
compared to the expression patterns
in normal epidermis. The expression
is enhanced and simultaneous
expression of the two markers
occurs.
C. Bcl-2 (green) and Bax (red): Bax
shows a low level of expression in
the basal cell layer but is
upregulated in the suprabasal layers
of the epidermis. The expression
patterns of Bcl-2 and Bax are
mutually exclusive.
D. Bcl-2 (green) and Bax (red): A
clear difference between the
expression patterns of Bcl-2 and
Bax in epidermis overlying BCC and
normal epidermis is that
simultaneous expression of Bcl-2
and Bax can occur in some
parabasal cells (see arrows).
E. Bax (red) and Ki-67 (green): The
expression patterns of Bax and Ki-
67 can show overlap in some
showing Ki-67 expression in the
Figure 3:
Proliferation- and
apoptosis
markers in the
BCC:
A. Bcl-2 (red) and
Ki-67 (green):
BCC stains
homogeneously
positive for Bcl-2,
while Ki-67 yields
positive staining at the periphery of the nodules. Morpheic strands show a more scattered pattern of
Ki-67 expression.
B. Bcl-2 (green) and Bax (red): BCC express Bcl-2 homogeneously, while Bax expression is found
in 60-90% of the tumor cells.
C. Bax (red) and Ki-67 (green): Simultaneous expression occurs in tumor cells (white arrows), while
also tumor cells are positive for Ki-67 but negative for Bax (yellow arrows).
The 40x objective was used for photography of images 3 A-C.
56
Materials and methods
Tissue material
Normal skin was obtained from breast reduction surgery at the Department of
Plastic Surgery of our hospital and was snap frozen in liquid nitrogen. Frozen
sections (5|am) were cut and placed on slides coated with 3-
aminopropyltrietoxysilan (APTS) (Sigma-Aldrich Chemie BV, Zwijndrecht, The
Netherlands).
Fresh frozen tumor material was obtained from 30 BCC patients treated by
Mohs' micrographic surgery. The histological classification of the BCCs showed
that twelve were nodular type, three were micronodular type, one was
morpheaform type, two were nodular/morpheaform type, six were
micronodular/morpheaform type, two were nodular/adenoid type and four were
mixed type (Table 3). In all these cases the apparently normal overlying
epidermis was also examined. Frozen sections (5nm) were cut and placed on
APTS-coated slides.
Methods
- Immunohistochemistry
Specificity of the polyclonal antibodies was warranted by the fact that they are
both affinity purified using the synthetic peptide used to immunize the rabbits.
Furthermore, immunoblotting was performed for the monoclonal- and polyclonal
antibody against Bcl-2 and the polyclonal antibody against Bax as was
described previously^, using the following cell lines: HeLa (human cervix
adenocarcinoma), HT29 (human colorectal adenocarcinoma), 3T3 (mouse
fibroblast), MCF-7 (human adenocarcinoma of the mammary gland), and Jurkat
(human T cell leukemia) (ATCC in Manassas, VA, USA). In addition, the
polyclonal antibodies against Bax and Bcl-2 were pre-absorbed with the
peptides used for immunization.
- Immunoperoxidase staining
Single antigen detection was performed using the immunoperoxidase staining
method^. Serial frozen sections were fixed in acetone and endogenous
peroxidase activity was quenched by incubating the slides with 0.3% hydrogen
peroxide in phosphate buffered saline (PBS). Nonspecific binding was blocked
by incubation with normal goat serum. The slides were then incubated overnight
at 4°C with the primary antibodies in optimal dilutions (Table 1).
The bound primary antibodies were linked with biotinylated secondary
antibodies. The sections were then incubated with Avidin-Biotin complex
horseradish peroxidase (Vector Laboratories Inc., Burlingame, CA, USA).
Peroxidase activity was detected with the chromogen 3,3'-diaminobenzidine
(DAB) and the sections were counterstained with haematoxylin (Fluka A.G.,
Buchs, Germany).
- Double-immunofluorescence staining
Serial frozen sections were fixed in acetone and nonspecific binding was
blocked by incubation with normal goat serum. The slides were then incubated
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with the primary antibodies, either subsequently or simultaneously, overnight at
4°C. Table 2 shows the combinations of antibodies that were used.
For combinations A and B (Table 2) the overnight incubation was followed by
incubation with peroxidase-conjugated goat-anti-mouse IgG (DAKO A/S,
Glostrup, Denmark) and subsequently incubation with a mixture of Texas Red-
labeled goat-anti-rabbit Ig (ITK Diagnostics, Uithoorn, The Netherlands) and
fluorescein isothiocyanate (FITC)-labeled tyramide^ to detect peroxidase
activity and simultaneous signal amplification.
For combinations C, D and E (Table 2), the slides were incubated with a mixture
of FITC-labeled goat-anti-mouse Ig and Texas Red-labeled goat-anti-rabbit Ig.
For combination F, overnight incubation with the polyclonal Bax antibody was
followed by incubation with biotinylated goat-anti-rabbit and Avidin-Biotin
complex (Vectastain ABC kit, Vector Laboratories Inc., Burlingame, CA, USA).
Detection of peroxidase activity and simultaneous signal amplification was
achieved by incubation with tetramethylrhodamine isothiocyanate (TRITC)-
labeled tyramide^. The slides were then incubated with the polyclonal Bcl-2
antibody and subsequently with FITC-labeled goat-anti-rabbit Ig (ITK
Diagnostics, Uithoorn, The Netherlands).
Determination of percentages of positive cells
The percentages of positive cells were estimated by counting 500 cells per
tumor by two independent observers.
Table 1: Antibody characteristics and dilutions used in the single label
immunoperoxidase staining procedure
Antibody
Clone 100 (monoclonal)
Clone 124 (monoclonal)
N-19 (polyclonal)
P-19 (polyclonal)
Ab-1 (polyclonal)
MIB-1 (monoclonal)
A0047 (polyclonal)
Epitope
Bcl-2 aa 44-52
Bcl-2 aa 41-54
Bcl-2 N-terminal
Bax N-terminal
Baxaa 150-165
Ki-67
Ki-67
Manufacturer
Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA
DAKO A/S, Glostrup, Denmark
Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA
Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA
Oncogene Research Products,
Cambridge, MA, USA
Immunotech, Marseille, France
DAKO A/S, Glostrup, Denmark
Abbreviation: aa = amino acids
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Table 2: Combinations of primary antibodies applied in the double-immunofluorescence
assay
Combination Antibodies and dilutions
A Clone 100 (1:10), N-19 (1:200), simultaneous incubation
B Clone 124 (1:50), A0047 (1:200), simultaneous incubation
C N-19 (1:200), MIB-1 (1:25), simultaneous incubation
D MIB-1 (1:25), P-19 (1:200), simultaneous incubation
E Clone 124 (1:50), P-19 (1:200), simultaneous incubation
F P-19 (1:1000), N-19 (1:200), subsequent incubation
Results
Specificity testing of the immunoreagentia
The specificity of the polyclonal- and monoclonal antibodies was warranted by
several tests. Firstly, the polyclonal antibodies against Bax and Bcl-2 were pre-
absorbed with the peptides used for immunization, resulting in absence of
staining when the corresponding peptide was used (Fig. 1A-D). Secondly, in
normal epidermis, the monoclonal antibody against Bcl-2 showed the same
expression pattern of the protein as seen with the polyclonal antibody (Fig. 1E
and F, respectively). In addition, the results of the immunoblotting showed the
expected 29 kDa band for both the monoclonal- and the polyclonal antibody
against Bcl-2 (Fig. 1G). Furthermore, the expected 21 kDa band for the
polyclonal antibody against Bax was seen (Fig. 1H).
Proliferation- and apoptosis markers in the epidermis
In normal skin, the expression of the Bcl-2 protein was found to be restricted to
the basal cell layer of the epidermis (Fig. 2A). This distribution pattern was seen
with the monoclonal as well as the polyclonal antibodies. Ki-67 expression was
found to be predominantly restricted to cells present in the parabasal layer, the
layer just above the basal cell layer (Fig. 2A). These cells were either scattered
throughout this layer, or clustered in certain areas. Again the polyclonal and
monoclonal antibodies gave rise to the same results. In general, the staining
patterns of Ki-67 and Bcl-2 were mutually exclusive, but occasionally some
basal cells showed simultaneous expression. Bax was found to be expressed in
the suprabasal layers of the epidermis, and in an occasional basal cell. The
double immunofluorescence studies revealed also mutually exclusive
expression of Bcl-2 and Bax proteins in normal skin (Fig. 2C). Bax and Ki-67
occasionally showed co-expression in the normal epidermis (Fig. 2E).
We noticed some striking differences in the epidermis overlying BCC as
compared to the epidermis of normal skin. Epidermis overlying BCC showed
increased numbers of cells positive for Ki-67, with suprabasal layers of the
epidermis also showing positive cells. With the monoclonal Bcl-2 antibody a
staining pattern similar to that in normal skin was seen, but when using the
polyclonal Bcl-2 antibody also para- and suprabasal cells showed positive
staining. As a result, cells with overlapping expression of Bcl-2 and Ki-67 were
shown (Fig. 2B). Also Bax and Bcl-2 could be detected simultaneously in the
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suprabasal layers of the epidermis overlying BCC (Fig. 2D). As in normal
epidermis, the Bax and Ki-67 staining patterns in the epidermis overlying BCC
occasionally showed co-expression (Fig. 2F).
Proliferation- and apoptosis markers in BCC (Table 3)
A homogeneous staining pattern was found for Bcl-2 in BCC throughout the
entire lesion, both for the polyclonal- and the monoclonal antibody. Expression
of Ki-67 was shown in the tumor cells at the periphery of most of the nodules in
the nodular type of BCC, and in a somewhat more variable pattern in the
morpheaform type of BCC. The percentages of Ki-67 expressing cells varied
greatly amongst the various histological types and within an individual tumor (6-
32%) with an average of almost 20% (Table 3). Areas with a high number of
cells expressing Ki-67 occurred however adjacent to areas with a lower number
of Ki-67 positive cells (Fig. 3A)
The expression of the Bax protein showed a scattered staining pattern which
varied among the different types of BCC and within the individual tumors (Fig.
3B), but on average it was found in approximately 80% of the tumor cells. The
percentages of cells showing simultaneous expression of Bax and Ki-67 varied
widely (4-25%) between tumors (Table 3 and Fig. 3C), and a correlation with
the histopathological type could not be found. The proliferative (Ki-67 positive)
fraction of the tumor consisted of cells either expressing or not expressing Bax.
It is shown in Figure 4 that within the proliferative compartment of each
individual tumor the percentage of Bax positive cells was higher than the
percentage of Bax negative cells.
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Figure 4: Bax status of the proliferative compartment
The graph represents the percentage of Bax positive and negative cells within the Ki-67
positive fraction. From this graph it can be seen that, in the proliferative compartment of
each individual tumor the percentage of Bax positive cells is higher than the percentage
of Bax negative cells.
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Table 3: Frequency of expression of proliferation- and apoptosis markers in BCC
Subtype
Nodular
Nodular
Nodular
Nodular
Nodular
Nodular
Nodular
Nodular
Nodular
Nodular
Nodular
Nodular
Nod/morph
Nod/morph
Nod/aden
Nod/aden
Morphea
Mnod/morph
Mnod/morph
Mnod/morph
Mnod/morph
Mnod/morph
Mnod/morph
Micronodular
Micronodular
Micronodular
Mixed
Mixed
Mixed
Mixed
Mean %
SD
Patient
number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Ki-67 +
9%
19%
27%
26%
22%
6%
17%
24%
23%
25%
8%
27%
21%
14%
23%
23%
32%
25%
32%
20%
14%
27%
22%
12%
15%
14%
23%
18%
12%
17%
19.7%
6.8%
Bax +
82%
87%
85%
83%
74%
77%
82%
82%
87%
80%
70%
82%
87%
81%
67%
77%
83%
60%
72%
78%
79%
80%
79%
88%
79%
87%
65%
76%
88%
77%
80.1%
7.0%
Ki-67+ /Bax-
3%
7%
10%
8%
4%
2%
8%
8%
7%
9%
3%
4%
5%
4%
12%
8%
10%
4%
6%
6%
5%
8%
4%
3%
6%
5%
11%
8%
4%
8%
6.4%
2.6%
Ki-67+ /Bax+
4%
11%
19%
17%
16%
3%
10%
16%
16%
15%
5%
21%
15%
13%
12%
14%
20%
25%
16%
16%
9%
19%
19%
10%
8%
8%
12%
12%
8%
16%
13.0%
5.2%
Abbreviation: Nod/morph = nodular/morpheaform, Nod/aden = nodular/adenoid
Mnod/morph = micronodular/morpheaform, SD = standard deviation
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Based on the different percentages of cells staining positive for the three
markers we can distinguish three different tumor cell fractions (Table 4). The
progressive fraction, which stains positive for Bcl-2 and Ki-67, but is negative for
Bax, accounts for 6.4±2.6% of the tumor cells. This fraction of cells may be
thought of as being responsible for the growth of the tumor since it is actively
proliferating and protected from undergoing apoptosis. The fraction of cells that
expresses all three markers may be regarded upon as proliferating but still
prone to apoptosis because of the presence of Bax. This fraction comprises
13.0±5.2% of the tumor cells. The third fraction (47±6.2%), expressing Bax and
Bcl-2, but lacking expression of Ki-67, is the non-proliferating fraction that is still
prone to apoptosis.
Table 4: Frequency of different cell populations in BCC
Cell fraction Marker pattern Percentage
Progressive Bcl-2+/Ki-67+/Bax- 6,4 ± 2,6
Proliferative, prone to apoptosis Bcl-2+/Ki-67+/Bax+ 13,0 ±5,2
Non-proliferative,prone to apoptosis Bcl-2+/Ki-67-/Bax+ 47,6 ± 6,2
Discussion
The growth rate in neoplastic lesions is often determined by both an increase in
the fraction of proliferating cells, as well as a decrease in the rate of cell loss^".
It has become apparent that in BCC an imbalance between apoptosis and
proliferation may explain its progression. Candidates for regulating the rate of
cell death are Bcl-2, which prevents apoptosis^"^, and Bax, which is known to
induce apoptosis^^°. These two proteins can form homo-dimers and hetero-
dimers, and their balance eventually determines whether the process of
apoptosis is induced or suppressed"'. To detect cell proliferation, Ki-67
antibodies are most widely used. They bind to a nuclear antigen expressed by
cycling cells^ ^.
Our results in normal skin are in concert with previously described studies,
showing Bcl-2 expression in the basal layer, Ki-67 expression in the parabasal
layer and Bax staining in a few basal cells, but predominantly in the suprabasal
layers"'**. Our double-label immuno-assays clearly demonstrated the almost
exclusive staining patterns for Ki-67 and Bcl-2 on the one hand, and for Bcl-2
and Bax on the other. A few cells, which are most likely responsible for the
regeneration of the epidermis, expressed both Ki-67 and Bcl-2. The expression
of Bax in the suprabasal compartment may reflect the commitment of these
cells to undergo terminal differentiation and eventually apoptosis, which also
explains the downregulation of Bcl-2 in these cells.
The expression of these markers in the epidermis overlying BCC has not been
studied extensively before. Our results showed Bax expression comparable with
that in normal epidermis, but expanded staining with the polyclonal Bcl-2
antibody in the epidermis overlying BCC. The differences in staining patterns
obtained by the monoclonal and polyclonal Bcl-2 antibodies may be explained
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by the recognition of different epitopes. The epitope recognized by the
monoclonal Bcl-2 antibody is apparently shielded in the suprabasal cell layers
by heterodimerization of Bcl-2 with other proteins, for example Bax. Similar
observations of epitope shielding have been described by Schandl ef aP.
The fraction of parabasal cells staining for Ki-67 was increased in the epidermis
overlying BCC as compared with that in the epidermis of normal skin, while also
more suprabasally located cells were Ki-67 positive. This suggests loss of cell
cycle control and maintenance of the Bcl-2/Bax status in the process of
migration of basal cells towards the suprabasal layer in the epidermis overlying
BCC. A significantly increased Ki-67 expression was also detected in the
hyperplastic epidermis overlying a keratotic melanocytic nevus, whereas Bcl-2
and Bax were expressed similarly in both normal and hyperplastic epidermis^.
This demonstrates increased proliferation in the context of adequately regulated
apoptosis.
A similar mechanism may explain the phenotype of BCC, in which a cell fraction
occurs which express both Bcl-2 and Ki-67, thus representing the actively
proliferating fraction. The percentage of these cells, which are double positive
for Ki-67 and Bcl-2, varied widely between tumors (6-32%) and also within the
individual tumors. A correlation between the histological type of the tumor and
the percentage of Ki-67 positive cells could not be found. Nevertheless, it may
be obvious that these double-positive cells play a key role in the progression of
the tumor, one reason being that they are prone to accumulation of genetic
modifications.
A comparison between the growth behavior of trichoepithelioma (TE), a benign
cutaneous tumor that originates from hair follicles", and BCC shows that BCC
and TE exhibit both differences in Ki-67 and Bcl-2 expression^ ^ . TE is a tumor
characterized by proliferation of keratinocytes that rapidly differentiate into
mature follicular cells, and which apparently cease to express Bcl-2. BCC is
composed of a population of basaloid keratinocytes, which largely retain their
ability to produce Bcl-2^. Furthermore, the number of Ki-67 expressing cells is
significantly higher in BCC^, which may explain the differences in growth
behavior between these tumors. The consistent lack of expression of Bcl-2 in
squamous cell carcinoma (SCC), a common malignant neoplasm that arises in
the skin, contrasts with the staining seen in BCCs and suggests that these
malignancies do not share the same cells of origin. Furthermore, their difference
in expression of Bcl-2 reflects their difference in regulation of cell turnover^.
In BCC cells, a variable Bax expression pattern was found. The relatively large
fraction of the cells expressing Bax in the tumor seems rather unexpected
because this protein is known to act as a tumor suppressor by enabling cell loss
through apoptosisiO. Previous studies on the expression of Bax in BCC
described conflicting results. Rossen ef a/" showed that the protein is not
expressed in BCC, whereas Delehedde ef aP demonstrated that the Bax
protein is in fact expressed in BCC. We found an expression pattern similar to
that of Delehedde ef aP, using the same antibody as used by Rossen ef aP.
However, we used frozen tissue sections, while these authors used paraffin
embedded material, which may explain the different results.
It was shown in previous studies"" ' ' that, based on morphology, the frequency
of apoptotic cells in different types of BCC ranged from 0.6% to 51%. This
corroborates our findings that approximately 80% of the BCC cells express Bax
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and is therefore prone to apoptosis. This relatively high percentage of Bax
expressing cells, combined with the relatively low fraction of the cells
expressing both Ki-67 and Bcl-2, may explain the slow progression rate of BCC.
In line with our finding that a relatively large proportion of the BCC cells express
the Bax protein, Mooney ef a/^  described that the apopfos/s: m/Yos/s ratio for
BCC was found to be 15.1, as compared to 2.1 for melanoma. Although the
finding by several authors that up to 50% of the BCC cells can be
apoptotic •^•", is now explained by the high percentages of cells expressing
Bax. The question remains whether Bcl-2 is still functional. Previous studies
already mentioned Bcl-2 mutations. Huang ef a/** showed that, when the serine
residue at position 70 of the Bcl-2 protein is altered into an alanine residue, the
anti-apoptosis function of the protein is diminished because the protein cannot
be dephosphorylated. Other inactivating mutations were deletion of the
conserved BH4 domain, as well as G145E and W188A mutations34.
Furthermore, Uhlmann ef a/^ showed that the deletion of a non-conserved
region between residues 51 and 85 of human Bcl-2 resulted in an enhanced
interaction with the death-promoting protein Bax, but no correlation with the
ability of Bcl-2 to interact with other proteins was observed.
In summary we can state that the results of our study show a relatively small
progressive cell fraction in BCC that is protected from apoptosis and actively
proliferating. The failure of these cancer cells to undergo programmed cell
death may contribute substantially to tumor progression. It has however also
become clear that a relatively high percentage of BCC cells express
considerable levels of Bax, a pro-apoptotic protein. In particular the presence of
this component in BCC may explain its indolent growth behavior.
> • • *
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Abstract
Background
Programmed cell death (apoptosis) is an important step in tissue homeostasis,
with members of the Bcl-2 protein family regulating this process. The delicate
balance between pro- and anti-apoptotic members of this family is disturbed in
several cancers.
Methods
Expression of the pro-apoptotic proteins Bid, Bad and Bcl-xs, activated
caspase-3, and the anti-apoptotic proteins Bag-1, Bcl-xl and 136SerP-Bad, and
two 14-3-3 variants known to interact with 136SerP-Bad, were
immunohistochemically studied in normal skin and basal cell carcinoma (BCC),
as well as in the apparently normal epidermis overlying BCC.
Results
In normal skin the basal layer of the epidermis stained homogeneously positive
for Bag-1, Bcl-xs, Bcl-xl, Bid and Bad, whereas the suprabasal cell layers
remained negative for Bag-1, Bcl-xs and Bid, while Bcl-xl and Bad were present
in the entire epidermis. 136SerP-Bad and cleaved caspase-3 showed a
scattered suprabasal pattern of expression in normal epidermis. 14-3-3.e
showed a homogeneous expression pattern in the entire epidermis, while 14-3-
3a was absent from the basal cell layer. The majority of tumors showed
homogeneous cytoplasmic staining for Bag-1, Bcl-xs, Bcl-xl, Bid and Bad,
whereas 136SerP-Bad was found in less than 10% of the tumor cells in all
cases and cleaved caspase-3 in less than 5%. 14-3-3.e was homogeneously
expressed in the tumors, while 14-3-3<r was predominantly expressed in the
central part of the tumors. The apparently normal epidermis overlying BCC
showed enhanced expression patterns for Bcl-xs, Bid, Bag-1 and 14-3-3a.
The low frequency of tumor cells showing activated caspase-3 was often found
to be localized in the central part of BCC tumor nests, which was mutually
exclusive with 136SerP-Bad which was found to be expressed in the periphery
of these tumor areas.
Conclusion
The pro- and anti-apoptotic markers studied show comparable patterns of
expression in the basal cell layer of normal epidermis and in BCC. In the
apparently normal epidermis overlying BCC, differences were seen in
expression patterns as compared to normal epidermis. This altered expression
may reflect a role of these constituents in the pathogenesis of BCC.
The presence of anti-apoptotic 136SerP-Bad positive cells in the peripheral cell
layers of tumor areas may be the result of growth stimulating effect on these
cells by surrounding survival factors. The central cells of these tumor nests are
largely devoid of these factors and are therefore subject to apoptosis as
indicated by caspase-3 activation.
Keywords: apoptosis, basal cell carcinoma, Bcl-2 family
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Introduction
The disturbance of the delicate balance between cell proliferation and cell
death, necessary for normal development and tissue homeostasis, may result in
development and progression of cancer^. We have recently reported a
imbalance between cell death and cell proliferation in basal cell carcinoma
(BCC) based on the immunohistochemical staining results for the anti-apoptotic
Bcl-2 protein, the pro-apoptotic Bax protein and the proliferation marker Ki-67^.
The study furthermore identified a small progressive cell population in BCC,
which could explain its indolent growth behavior. However, in recent years, a
large number of Bcl-2 related proteins have been isolated that serve as critical
regulators of apoptosis, acting either to inhibit or to promote cell death"* ^ . This
family of proteins can be subdivided into three categories.
The first category consists of the anti-apoptotic members such as Bcl-2^ and
Bcl-xf that share homology in four Bcl-2 sequence homology (BH) regions*® ,
i.e. BH1 to BH4®. The second category consists of pro-apoptotic members, such
as Bax10 and Bak11 that share sequence homology in BH1 to BH3, but not in
BH4. The third category comprises the 'BH3-only proteins', such as Birm", Bid"
and Bad'*, all with a pro-apoptotic activity^. Heterodimerization between these
anti- and pro-apoptotic family members can occur^'®. The balance in the
expression of Bcl-2 family members is an important determinant of the cells'
fate. Furthermore, modification of the Bcl-2 family members, e.g. by
phosphorylation, dephosphorylation or cleavage by activated caspases will
determine their functional properties. Bad can become phosphorylated under
the influence of several growth factors, upon which the protein interacts with 14-
3-3 proteins and remains inactive in the cytosol^. Bid becomes cleaved by
activated caspase-8*° upon which the C-terminal fragment can translocate to
the mitochondria to induce cytochrome C release^. Another protein associated
with prolonged cell survival is Bag-1, which can bind to Bcl-2, enhancing its anti-
apoptotic effect^. The potential contribution of these Bcl-2 family members to
the pathogenesis of BCC is still largely unknown, although a possible role in
other types of malignancies has been described"'". To examine the potential
contribution of these Bcl-2 family members and associated proteins to the
pathogenesis of BCC, we immunohistochemically investigated their expression
patterns in frozen sections of normal skin, apparently normal epidermis
overlying BCC, and 24 cases of this malignancy. An imbalance between these
pro- and anti-apoptotic constituents should result in apoptosis in a certain
percentage of (tumor) cells. This fraction of cells is estimated using an antibody
to activated caspase-3, an executioner caspase stimulated via different routes
of apoptosis induction^.
Materials and Methods
Tumor samples
Normal skin biopsies (n = 5) were obtained by breast reduction surgery at the
Department of Plastic Surgery, and the BCC (n = 24) samples were obtained by
Mohs' micrographic surgery at the Department of Dermatology of our hospital.
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These specimens comprised 12 cases of the nodular type, 2 cases of the
micronodular type, 5 cases of the morphea type, 3 cases of the nodular-
morphea type, 1 case of the micronodular-morphea type, and 1 case of the
mixed type. The samples were snap frozen in liquid nitrogen and stored at -
80°C until used. Serial sections (5(jm) were cut and placed on 3-
aminopropyltriethoxysilan (APTS; Sigma-Aldrich Chemie BV, Zwijndrecht, The
Netherlands)-coated slides. The histopathologic diagnosis was established
using haematoxylin (Fluka AG, Buchs, Germany) and eosin (BDH Laboratory
Supplies, Poole UK) staining.
Immunohistochemistry
After fixation in acetone (-20°C), the slides were incubated with the primary
antibodies, overnight at 4 C. Table 1 shows the antibodies used in this study
and the dilutions applied. The antibodies were diluted in 1% bovine serum
albumin (BSA; Roche Diagnostics GmbH, Mannheim, Germany) in PBS to
block non-specific binding.
The primary antibodies against Bag-1, Bcl-xl, Bcl-xs, 136SerP-Bad, 14-3-3eand
14-3-3a were detected with peroxidase-conjugated secondary antibodies
depending on the Isotype of the primary antibodies. Peroxidase activity was
detected using the chromogen 3,3'-diaminobenzidine (DAB; Sigma-Aldrich
Chemie BV, Zwijndrecht, The Netherlands), and the sections were
counterstained with haematoxylin. For the detection of Bid further enhancement
of the signal was necessary. After incubation with the peroxidase-conjugated
secondary antibody, the slides were incubated with biotin-conjugated tyramide
(Dupont NEN, Boston, MA, USA), followed by incubation with peroxidase-
conjugated avidin (DAKO A/S, Glostrup, Denmark). The peroxidase activity was
then detected using DAB and the slides were counterstained using
haematoxylin. Detection of Bad and activated caspase-3 required blocking of a-
specific staining prior to incubation with the primary antibody. The slides were
incubated using 5% normal goat serum (NGS)/PBS for 1 hour at room
temperature. Following this incubation, the slides are incubated with the primary
antibody overnight at 4°C. After incubation with the secondary antibody, the
ABC-detection kit was used. The peroxidase activity was then detected using
DAB and the slides were counterstained using haematoxylin. As a negative
control for all antibodies, the primary antibodies were omitted.
Evaluation of the frequency of positive cells was as follows: - absence of
staining; +/- staining in a small fraction of cells i.e. less than 10%; + staining in
most tumor cells i.e. more than 75%; ++ homogeneous staining pattern.
Results
The staining results of the antibodies against Bcl-xs, Bcl-xl, Bid, Bad, 136SerP-
Bad, 14-3-3-e, 14-3-3-CT, Bag-1 and cleaved caspase-3 are summarized in Table
2 and depicted in Fig.1.
71
Table 1 : Antibody characteristics and their dilutions used in the immunoperoxidase
staining procedure
Antibody Manufacturer Dilution
Bad, polyclonal IgG
136SerP-Bad, polyclonal IgG
Bag-1, polyclonal IgG
Bcl-xl, monoclonal lgG2a
Bcl-xs, rabbit polyclonal IgG
Bid, polyclonal IgG
Activated caspase-3, polyclonal IgG
14-3-3t, monoclonal IgM
14-3-3a monoclonal lgG1
Cell Signaling Technology, Beverly, MA.USA 1:50
Santa Cruz Biotechnology Inc., Santa Cruz, CA.USA 1:50
Santa Cruz Biotechnology Inc., Santa Cruz, CA.USA 1:200
Zymed Laboratories Inc., San Francisco, CA.USA 1:50
Oncogene Research Products, Cambridge, MA,USA 1:25
Santa Cruz Biotechnology Inc., Santa Cruz, CA.USA 1:100
Cell Signaling Technology, Beverly, MA.USA 1:50
BD Transduction Laboratories. Heidelberg,Germany 1:250
Biocarta, San Diego, CA.USA 1:100
Normal skin Epidermis overlying BCC
Figure 1 : Expression patterns of pro- and anti-apoptotic members of the Bcl-2 family and
associated proteins in skin and BCC. Original magnifications used for images A,B,D,E,G-
K.M-0 20x, images C,F,L 40x.
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Normal skin
In normal skin, the basal cell layer of the epidermis stained homogeneously
positive for Bcl-xs (Fig.1A), Bcl-xl, Bid, Bad, 14-3-3-e and Bag-1 (Fig.U),
whereas the suprabasal cell layers remained negative for Bcl-xs, Bid and Bag-
1, while Bcl-xl, Bad and 14-3-3-E were expressed homogeneously in the
suprabasal cell layers. 136SerP-Bad (Fig.1D) was detected in a small fraction of
cells in the epidermis, as was cleaved caspase-3 (Fig.1M). 14-3-3-a (Fig.1G)
was negative or present only in a small fraction of basal cells, but
homogeneously expressed in the suprabasal cells.
Epidermis overlying BCC
Bcl-xs stained homogeneously positive in the basal layer of the epidermis
overlying BCC in all of the 24 cases and was homogeneously positive in the
suprabasal layers in 9 of the 24 cases (38%). Further 9 cases showed positive
staining in the majority of suprabasal cells (Fig.1B), while 4 cases (17%)
showed occasional immunoreactivity in the suprabasal cells. The remaining 2
cases (8%) remained negative in the suprabasal layers. Bcl-xl stained the entire
epidermis homogeneously positive in all 24 cases. Bid staining was
homogeneous in the basal cell layer of all 24 cases, 10 cases (42%) showed
occasional immunoreactivity in the suprabasal cells, while the remaining 14
cases (58%) remained negative in the suprabasal cell layers. Bad was
homogeneously expressed in all cell layers in all cases, whereas 136SerP-Bad
(Fig.1E) was present in only a small fraction of epidermal cells in all cases. 14-
3-3-e. was homogeneously expressed in the entire epidermis in all cases,
whereas 14-3-3-q (Fig.1H) is expressed in a small fraction of basal cells but
homogeneously in the suprabasal cells in all cases. All 24 cases showed
homogeneous cytoplasmic staining of the basal cell layer for Bag-1 and 10
cases (42%) showed negative staining in the suprabasal layers. However, 5
cases (21%) stained homogeneously positive in the suprabasal cell layers and
5 cases showed Bag-1 staining in the majority of suprabasal cells (Fig.1K). The
remaining 4 cases (17%) showed occasional immunoreactivity for Bag-1 in the
suprabasal cell layers. Cleaved caspase-3 is expressed in a small fraction of
epidermal cells in all cases (Fig.1N).
Basal cell carcinoma
Bcl-xs staining resulted in a homogeneous cytoplasmic staining all BCCs
studied (Fig.1C). Staining for Bcl-xl resulted in a homogeneous cytoplasmic
staining in 19 of the 24 cases (79%), 2 cases (8%) showed partial positivity in
some fields and homogenous staining in other fields, while one case showed
only occasional positive staining in cells mainly located in the center of the
tumor, and 2 cases remained negative. Bid staining resulted in a homogeneous
cytoplasmic staining in 22 of the 24 cases (92%), while the remaining 2 cases
showed either partial positivity, or a combination with a homogeneous staining
in some fields. Bad was homogeneously detected in 18 cases (75%), while 6
cases showed immunoreactivity in the majority of cells. In contrast, 136SerP-
Bad immunopositivity was detected in a small fraction (<10%) of the tumor cells
(Fig.1F) in the majority of cases (71%), whereas the remaining tumors showed
no expression of 136SerP-Bad. 14-3-3-e was homogeneously expressed in all
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cases, whereas 14-3-3-awas present in the majority of tumor cells,
predominantly located in the center of the tumor nests (Fig.11) in all cases. Bag-
1 staining of the BCCs resulted in a homogeneous cytoplasmic staining (Fig.1L)
in 23 of the 24 cases (96%), 1 case showing partial positivity in some fields and
homogeneous staining in other fields. Cleaved caspase-3 was detected in a
small fraction of tumor cells (approximately 5%) in all cases (Fig. 10) and was
often predominantly located in the central part of the tumor nests.
Table 2: Expression patterns of pro- and anti-apoptotic members of the Bcl-2 family and
associated proteins in skin and BCC
Normal Skin
Epidermis overlying
BCC
BCC
basal cells
suprabasal cells
basal cells
suprabasal cells
lumor cells
Bcl-xs
pro
••(5/5)
•(4/5)
•+ (24/24)
++ (24/24)
Bcl-xl
anl/
+•(5/5)
++(4/5)
+ (1/5)
++ (24/24)
•+ (24/24)
++ (19/24)
+ (2/24)
•/-(1/24)
-(2/24)
Bid
pro
++ (5/5)
-(5/5)
+• (24/24)
- (14/24)
•/-(10/24)
•• (22/24)
+ (1/24)
•/-(1/24)
Bad
pro
•• (5/5)
•• (3/5)
+ (2/5)
++ (24/24)
•+ (24/24)
++ (18/24)
+ (6/24)
P-Bad
and
• M M )
+M5/5)
+/- (24/24)
+/• (24/24)
+/• (17/24)
-(7/24)
14-3-3»-
++(5/5)
•+(5/5)
++ (5/5)
++(5/5)
++ (24/24)
14-3-3°
-(3/5)
++(5/5)
+/-(24/24)
++(24/24)
+ (24/24)
Bag-1
anfi
•+ (5/5)
•(5/5)
+• (24/24)
-(10/24)
+• (5/24)
• (5/24)
•• (2304)
•(1/24)
Capase-3
•/• (5/5)
•/-(5/5)
•/• (24/24)
+/- (2404)
•/• (24/24)
Abbreviations: pro = pro-apoplolic protein, anli = anti-apoptotic protein
-; negative
+/•; positivity in a small fraction of cells <10%
+; positivity in majority of cells >75%
••; homogeneously positive
(x/y); number of positive cases over total number of cases
Discussion
The development of cancer is accompanied by disturbances in cell cycle
regulation as well as by the suppression of programmed cell death, i.e.
apoptosis\ In an earlier study'' we suggested that in BCC only a small
population of tumor cells combines these features. We came to this conclusion
on basis of the simultaneous expression of the proliferation marker Ki-67 and
the anti-apoptotic Bcl-2 protein, in the absence of the pro-apoptotic Bax protein.
The control of apoptosis is, however more complex, involving many more pro-
and anti-apoptotic constituents and associated proteins'*®. This study aims at
establishing the role of the specific apoptosis-regulating members of the Bcl-2
family and associated proteins in skin carcinogenesis by studying their
expression patterns in normal human skin and BCC through
immunohistochemical assays.
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As shown in this study a number of pro- and apoptotic members of the Bcl-2
family, i.e. Bag-1, Bcl-xs, Bid and as described before also Bcl-2^ are largely
restricted to the basal cell compartment of the normal epidermis. In virtually all
BCCs studied, these four constituents were found to be homogeneously
expressed and to exhibit a cytoplasmic localization. Thus, the basal cell
phenotype with respect to apoptosis regulating proteins is clearly reflected in
BCC by these markers.
High expression of anti-apoptotic Bag-1 protein has in general been correlated
with a predisposition for more aggressive behavior of the tumor and less
favorable clinical outcome, probably by enhancing the anti-apoptotic activity of
Bcl-2^. In oral squamous cell carcinomas, high Bag-1 expression was
frequently correlated with nodal metastasis^. Furthermore, over-expression of
Bag-1 leads to progression of malignant melanoma and promotes metastasis to
^°. In patients with invasive breast carcinomas, Bag-1 expression, mainly
*
ly
located at the nucleus, correlated with less favorable clinical outcome'* .
Laryngeal carcinoma patients furthermore showed that nuclear Bag-1
expression correlated with a significantly lower survival rate after radiotherapy^.
Because of its apparent correlation with highly aggressive behavior, the
relatively abundant expression of Bag-1 in BCC is quite surprising since these
tumors in general exhibit an indolent clinical behavior. However, in our study
Bag-1 showed a cytosolic localization in normal skin as well as in BCC, which
may explain this apparent discrepancy.
Bcl-xl and Bcl-xs are both splice variants of Bcl-x^, Bcl-xs exerting pro-apoptotic
and Bcl-xl anti-apoptotic effects. Whereas Bcl-xs is expressed only in the basal
cells of normal skin, Bcl-xl is expressed homogeneously throughout the entire
epidermis, and has been shown to be essential for protecting skin and other
epithelial cells from apoptosis^. Furthermore, it was shown that the Bcl-xl
expression level increases from primary melanoma to melanoma-metastases,
whereas Bcl-xs expression decreases during melanoma progression. This may
reflect an increased malignant potential caused by an inhibition of apoptosis
and growth advantage for metastatic melanoma cells^. In our study, Bcl-xs
expression was homogeneous in all BCCs, while 19 of the 24 cases showed
also homogeneous expression of Bcl-xl in the tumors, indicating a delicate
balance between these two Bcl-2 family members.
The pro-apoptotic protein Bid is normally activated by cleavage through
caspase-8, after which the C-terminal fragment translocates to the mitochondria
where it induces cytochrome C release . High levels of Bid expression were
reported previously in locally advanced prostate cancer^, where it was
associated with longer recurrence-free survival. It was furthermore stated that
the apoptosis-inducing Bid could possibly be of great importance in positive
tumor responses to specific chemotherapeutic drugs. These studies and the
underlying experiments can however not discriminate between intact Bid and its
C-terminal fragment, because of the absence of antibodies specific for the
latter.
Furthermore, the enhanced expression of Bag-1 in the suprabasal cell layers of
the apparently normal epidermis overlying BCC, as compared to control
epidermis, may indicate subtle pre-neoplastic changes that occur in this tissue.
A similar result was obtained for Bcl-2 in our earlier study^ on BCC. The anti-
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apoptotic effects of Bag-1 and Bcl-2 in this tumor overlying epidermis may
however be (partially) compensated for by enhanced expression of pro-
apoptotic Bcl-xs. These findings in skin overlying BCC, with apoptosis
regulating proteins typically found in basal cells of normal skin, do however
show that this apparently normal epidermis exhibits a phenotype in-between
that of normal skin and BCC. A similar conclusion was drawn from studies on
the expression of the proliferation marker Ki-67 and of the nuclear A-type
lamins .
A remarkable result was found for the expression pattern of 14-3-3n. in the
epidermis of normal skin and BCC. In normal skin, the basal cell layer of the
epidermis remains negative, a phenomenon also shown by the outer (basal) cell
layers of the tumor nests. This supports the earlier hypothesis that the basal cell
phenotype is clearly reflected in BCC.
Furthermore, the expression patterns of 136SerP-Bad and cleaved caspase-3
seem to be mutually exclusive in the BCCs we studied. Where cleaved
caspase-3 positive cells are mainly located in the central part of the tumor
nests, the 136SerP-Bad positivity is predominantly located at the periphery.
This suggests, that the presence of surrounding survival factors results in
survival and consequent progression of the peripherally located cells, whereas
the central cells of these tumor nests are largely devoid from these factors and
are therefore subject to apoptosis.
In conclusion we can state, that while BCC shows a remarkable basal cell like
phenotype, the epidermis overlying BCC shows a phenotype in between that of
normal skin and BCC. Whether this phenomenon is induced by factors
generated by the BCC or can be regarded as a first step in skin carcinogenesis
remains to be established. Furthermore, the 10% of tumor cells that are positive
for 136SerP-Bad reflect the progressing fraction of the tumors and corroborate
our earlier finding that approximately 6% of the tumor cells represent the
progressive fraction^. We can thus conclude that several members of the Bcl-2
family indicated that the balance between anti- and pro-apoptotic proteins plays
an important role in the progression of BCC.
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Abstract
Background
Aberrant expression patterns of nuclear lamins have been described in various
types of cancer depending on the subtype of cancer, its aggressiveness,
proliferative capacity and degree of differentiation. In general, the expression of
A-type lamins (lamins A and C) has been correlated with a non-proliferating,
differentiated state of cells and tissues.
Objectives
To establish and compare the expression patterns of lamins in normal human
skin, actinic keratosis (AK), squamous cell carcinoma (SCC) and basal cell
carcinoma (BCC).
Methods
Expression patterns of the individual lamin subtypes were studied
immunohistochemically. The proliferation capacity of the tumor cells was
detected using a specific antibody to Ki-67, and was related to the A-type lamin
expression patterns.
Results
In normal skin, lamin A was expressed in the suprabasal cell compartment of
the epidermis, whereas the basal cells were mostly unstained. BCCs and SCCs
stained positive in the most cells, while the epidermis overlying BCC and SCC
and the epidermis in AK stained homogeneously and strongly in the basal cells
in addition to the suprabasal cells. Lamin C was expressed in some basal cells
of normal epidermis, while the suprabasal cells stained strongly positive. Both
BCCs and SCCs stained strongly positive for lamin C, with the difference that in
BCC the staining was predominantly present in nucleolar structures with
occasional staining of the nuclear envelope. The epidermis overlying SCC
showed strong positivity in the lamina of virtually all cells. The expression of
lamin C in the basal cells of AK resembled the expression pattern seen in the
epidermis overlying BCC, i.e. a nucleolar staining next to nuclear envelope
staining. Lamin B1 and B2 were found in virtually all cells in normal epidermis,
AK, BCCs, SCCs and the epidermis overlying cancer. The percentage of Ki-67
expressing cells was highest in BCC (45%), and gradually decreased via
epidermis overlying BCC, AK, SCC, epidermis overlying SCC to normal skin
(11%). Simultaneous expression of A-type lamins and Ki-67 occurred in
approximately 50% of the proliferating (Ki-67 positive) cells in BCC and SCC.
Conclusion
Significant changes occur in the expression patterns of A-type lamins in both
pre-malignant and malignant lesions of the skin. The profound overlap of lamin
A and Ki-67 staining patterns indicates that the proliferating tumor cells may
obtain a certain degree of differentiation. Finally, lamin A expression in the
basal cell layer of the apparently normal epidermis overlying BCC may suggest
its involvement in the primary process.
Keywords: actinic keratosis, basal cell carcinoma, epidermis, lamins,
proliferation, squamous cell carcinoma
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Introduction
Nuclear lamins are intermediate filament proteins that form a network at the
nucleoplasmic site of the nuclear membrane. Two subtypes of nuclear lamins
exist in humans, i.e. A-type lamins (also designated Statins), including lamin A,
lamin AA10 and lamin C, all three arising from the same gene by alternative
splicing^, and B-type lamins, i.e. lamin B1 and lamin B2, arising from two
distinct genes"'''. In general, the A-type lamins are expressed in differentiated
cells and tissues, whereas B-type lamins are also expressed in undifferentiated
cells. From previous studies it became clear that the expression of both A-type
lamins and B-type lamins is differentially regulated in human tissues^ and during
embryogenesis .
Lamins share many characteristics with the other intermediate filament
subclasses, but they are located exclusively in the nucleoplasm instead of the
cytoplasm. A nuclear localization signal at the carboxy- terminus directs the
transport into the nucleus^. Furthermore, the nuclear lamins form two-
dimensional sheets underlying the nuclear membrane, while cytoplasmatic
intermediate filaments form fibrous structures extending from nucleus to plasma
membrane®.
Although many biochemical and molecular features have been studied, the
function of the lamins remains largely undetermined. It can be assumed that
nuclear lamins not only maintain the integrity of the nucleus and the position of
nuclear pore complexes, but are also thought to be important in maintaining the
interphase organization of chromatin^ and may be involved in the regulation of
gene expression^•". Spann ef a/^ showed that alteration of lamin organization
inhibits transcription and thereby regulates gene activity.
Aberrant expression patterns of lamins have been described in cancer. The
nuclear matrix may play a role in cancer development as a result of alterations
in protein expression during transformation^. Earlier studies have shown that
lamin expression in some tumors is dependent on the subtype of cancer, its
aggressiveness, proliferative capacity and degree of differentiation^'^. In
general, A-type lamin expression is correlated with a non-proliferating,
differentiated state of cells and tissues®, and therefore one would expect an
altered expression of A-type lamins in cancer. In basal cell carcinoma (BCC),
Venables ef a/." have recently demonstrated that the absence of lamin A
correlated with rapid growth, while the absence of lamin C correlated with slow
growth of this skin tumor.
Furthermore, proteolytic lamin degradation has been shown in apoptotic cells^
and this degradation seems to proceed DNA fragmentation^. The presence of
artificially introduced degradation-resistant lamins delays the process of
apoptosis^", suggesting that the nuclear lamins play an important part in the
process of apoptosis by facilitating nuclear events during apoptosis, such as
chromatin condensation. Since differences exist in the fraction of apoptotic cells
in squamous cell carcinoma (SCC) and BCC^'^, a comparison was made of
lamin staining patterns in these malignancies.
Thus, this study aims at establishing and comparing the expression patterns of
lamins in normal human skin, actinic keratosis (AK), SCC and in BCC in order
to investigate the role of lamins in the process of skin carcinogenesis.
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Materials and methods
Tissues
Samples of normal human skin (n=5) were obtained from reduction surgery of
human breast or abdomen. The BCC samples (n=15) were obtained from Mohs'
micrographic surgery. The AK (n=5) and SCC (n=10) specimens were obtained
from biopsies. All specimens were snap-frozen in isopentane and 5 ^m sections
were cut onto 3-aminopropyltrietoxysilan (APTS; Sigma-Aldrich Chemie BV,
Zwijndrecht, The Netherlands) -coated slides, air-dried and fixed in acetone (10
minutes, -20°C).
Table 1: Antibodies and their dilutions used in this study
Clone/Name
41CC4
R27
133A2
RaLC
119D5F1
LN43
X223
A0047
isotype
mouse IgM
mouse IgM
mouse lgG3
rabbit polyclonal
mouse IgG,
mouse IgG,
mouse IgG,
rabbit polyclonal
Antigen I
Lamins A/C
Lamins A/C
Lamin A
Lamin C
Lamin B1
Lamin B2
Lamin B2
Ki-67
Dilutio
ud
ud
1/500
1/50
1/250
ud
ud
1/200
Burke ef a/., 1983^
Zatloukalefa/., 1992"
Abeam Ltd..Cambridge, UK™
Abeam Ltd.,Cambridge, UK"
Abeam Ltd.,Cambridge, UK**
Abeam Ltd..Cambridge, UK*°
Research Diagnostics, NJ.USA*
DAKO A/S, Glostrup, DK
Abbreviation: ud = undiluted
Immunohistochemistry
Table 1 shows the antibodies that were used in both immunoperoxidase and
immunofluorescence staining procedures.
-Immunoperoxidase staining protocol:
All incubations were carried out at room temperature in a moist chamber. After
incubation with the primary antibody for 1 hour, the slides were rinsed with
phosphate buffered saline (PBS) (3x 5 minutes). Then, a secondary antibody
(either goat-anti-mouse IgG (SBA, Birmingham, AL, USA) or swine-anti-rabbit
IgG (DAKO A/S; Glostrup, DK), dependent on the primary antibody) conjugated
with peroxidase, was used to incubate the slides for 1 hour (1:100 diluted in
PBS). After rinsing with PBS the slides were then incubated with 3,3'-
diaminobenzidine (DAB; Sigma-Aldrich Chemie BV), 1:10 diluted in PBS +
0,03% H2O2, for 15 minutes. The slides were then rinsed with water for 15
minutes. Counterstaining was carried out with haematoxylin (Sigma-Aldrich
Chemie BV). After dehydration the slides were embedded with Entellan
(MERCK, Darmstadt, Germany).
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-Immunofluorescence staining protocol:
After overnight incubation at 4°C with the primary antibody, the slides were
rinsed with PBS (3x 5 minutes). Then, a secondary antibody (dependent on the
primary antibody either goat-anti-mouse IgG or goat-anti-rabbit IgG), conjugated
with a fluorescent label, was used to incubate the slides for 1 hour (1:100
diluted in PBS) at room temperature. After rinsing with PBS the slides were then
embedded with TRIS-glycerol (pH 8.0) containing 0.5 (.ig mL"^  4', 6-diamidin-2-
phenylindol-dihydrochloride (DAPI; Sigma-Aldrich Chemie BV).
Lamin A and Lamin C could be detected simultaneously using a mix of 133A2
(mouse monoclonal antibody) and RaLC (affinity purified rabbit antiserum) for
the incubation. The mix of secondary antibodies consisted of fluorescein
isothiocyanate (FITC)-labeled goat-anti-mouse (DAKO A/S) and a Texas Red-
labeled goat-anti-rabbit antibody (SBA). Lamin A and Ki-67 were detected
simultaneously using a mix of 133A2 and the rabbit polyclonal serum A0047.
Table 2: Major lamin expression patterns in normal skin, actinic keratosis (AK),
squamous cell carcinoma (SCC) and basal cell carcinoma (BCC)
Tissue Lamin A Lamin C Lamin B1 Lamin B2
Normal skin (n = 5)
basal layer - +/- ^ + +
suprabasal layers + + + +
AK (n = 5)
basal layer ++ + (nucleoli/lamina) + ++
suprabasal layers + + (nucleoli) +/- +
SCC(n = 10) ++ + + +
Epidermis overlying SCC
basal layer ' ++ + +/- +
suprabasal layers + + +/- +
BCC(n = 15) ++ + (nucleoli) + +
Epidermis overlying BCC
basal layer ++ + (nucleoli/lamina) + +
suprabasal layer + + (nucleoli/lamina) + +
- no staining, +/- staining in small fraction of the cells , + positive staining in most cells,
++ positive staining in all cells
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Results
Table 2 shows the major lamin expression patterns in normal skin, AK, SCC
and BCC.
Lamin expression in normal skin and actinic keratosis
Lamin A was found predominantly in the suprabasal cell layers of the normal
epidermis (Fig. 1A), while lamin C was occasionally present also in the basal
cell (Fig. 1B). Stromal cells stained positive for both lamins A and C. In AK,
lamin A was expressed in all cells of the basal layer as well as in most cells of
suprabasal layers in all cases (Fig. 1C). Lamin C was found in the most basal
and suprabasal cell layers in all cases, showing a predominant nucleolar
localization (Fig. 1D).
B-type lamins were found to be expressed throughout the entire epidermis (Fig.
2A,B), which was similar to the pattern seen in AK. Stromal cells only seldomly
stained positive for lamin B1, whereas lamin B2 was present in these cells.
Lamin expression in squamous cell carcinoma
Lamin A was detected in all or most cells in the basal and suprabasal cell layers
of the apparently normal epidermis overlying SCC, whereas lamin C was
expressed in all or most basal cells and in all cells in the suprabasal cell layers
of the apparently epidermis overlying SCC (Fig. 3A,B). The B-type lamins
showed slightly reduced expression levels in the basal cell layer of the
epidermis overlying SCC as compared to normal skin.
Lamin A was detected in all or most tumor cells, with lamin C being expressed
in most tumor cells of all cases, both showing a nuclear lamina staining (Fig:
3C,D). B-type lamins were found in most tumor cells.
Lamin expression in basal cell carcinoma
In the apparently normal epidermis overlying BCC, lamin A (Fig. 4A) could be
detected in all or most cells in the basal cell layer. Only one case showed
expression in a small fraction of the basal cell layer. Most cells in the
suprabasal layers stained positive. For lamin C (Fig. 4B), most cases stained
positive in all or most basal cells while four cases showed staining in a small
fraction of the basal cells. Most or a small fraction of cells stained positive in the
suprabasal layers. The staining was predominantly present at the nucleoli.
Lamin B1 showed positivity in all or most cells in the basal cell layer, while a
small fraction of cells in the suprabasal layers stained positive. Lamin B2 was
detected in all or most cells in the basal and suprabasal cell layers.
In BCC, lamin A stained positive in all or most tumor cells, showing a nuclear
envelope localization (Fig. 4C). Lamin C stained positive in all or most tumor
cells. Only one case expressed lamin C in a small fraction of tumor cells. The
staining was predominantly localized in the nucleoli (Fig. 4D), while in two cases
the nuclear envelope was also stained. Lamin B1 expression was detected in all
or most tumor cells, only one case showing staining in a small fraction of tumor
cells. Lamin B2 stained positive in most tumor cells.
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Ki-67/lamin A co-expression
Ki-67 positivity in normal human epidermis was mainly restricted to the
suprabasal cell layers of the epidermis; these cells were either scattered
throughout this layer, or clustered in certain areas, with an average of 11%
positive cells (Fig. 5A).
In BCC, Ki-67 stained positive in the tumor cells at the periphery of most of the
nodules in the nodular type, and in a somewhat more variable pattern in the
morpheaform type. However, areas with a high number of cells expressing Ki-
67 occurred adjacent to areas with a lower number of Ki-67 positive cells. The
average of Ki-67 expressing tumor cells in BCC was 45%. The epidermis
overlying BCC also snowed increased numbers of cells positive for Ki-67 (35%)
as compared to the epidermis in normal human skin with suprabasal layers of
the epidermis also showing positive cells (Fig. 5B). In SCC, Ki-67 expression
was predominantly located at the periphery of the nodules with an average of
20% of tumor cells being positive. The epidermis overlying SCC showed an
average of 18% of cells expressing Ki-67. AK showed an average of 31% of Ki-
67 expressing cells in the epidermis.
Co-expression of lamin A and Ki-67 occurred in 62% of the proliferating (Ki-67
positive) tumor cells in BCC (Fig. 5C) and in 56% of the tumor cells in SCC.
Discussion
Previous studies have shown that the nuclear lamina participates in interphase
chromatin organization, DNA replication and gene expression®"^. Its integrity
seems instrumental in the regulation of apoptosis^. Therefore, it is possible that
changes in the lamina can affect the balance between cell proliferation and
apoptosis in various cell types. In this study we investigated the differential
expression patterns of the nuclear lamins in normal human skin, AK and in non-
melanoma skin cancers SCC and BCC.
The lamin A expression in the basal cell layer of the epidermis overlying BCC,
SCC and AK, in contrast with its exclusively suprabasal localization in normal
skin, may suggest an involvement of these basal cells in the carcinogenic
process. Also, it cannot be excluded that factors originating from the tumors
may induce this differentiated-like phenotype of the basal cells. Furthermore,
based on this abnormal expression pattern, antibodies against lamin A may be
used to differentiate between normal human skin and diseased skin. With
respect to lamin A expression in BCC, a striking difference was observed when
comparing our results with these of Venables ef a/.". Although similar
distribution patterns were obtained in normal human skin, and a partially
overlapping panel of antibodies was applied, we found a higher frequency of
lamin A expressing cells in BCC.
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basal, as well as in the suprabasal cell layers.
Original magnification used for photography of images A-D was 20x.
Figure 1: A-type lamins in normal
human skin and actinic keratosis
A. Lamin A (133A2); predominantly
found in the suprabasal cell layers
of the epidermis of normal human
skin.
B. Lamin C (RaLC); occasionally
present in basal cells next to a
more homogeneous expression in
the suprabasal layers of the
epidermis of normal human skin.
C. Lamin A (133A2); expressed in
the basal cell layer as well ass in
the majority of the cells in the
suprabasal cell layers in actinic
keratosis.
D. Lamin C (RaLC) showing a
nucleolar staining pattern in the
Figure 2: B-type lamins
in normal human skin.
Lamin B1 (119D5F1, A)
and Lamin B2 (LN43, B)
are both expressed
throughout the entire
epidermis of normal
human skin.
Original magnification
used for photography of
images A and B was 20x.
Figure 3: Lamin expression in
squamous cell carcinoma and in
the epidermis overlying
squamous cell carcinoma
A: Lamin A (133A2) showing a
homogeneous staining of the
basal cells of the epidermis
overlying squamous cell
carcinoma, the majority of the
suprabasal cells also staining
positive.
B: Lamin C (RaLC); also
expressed in the majority of cells
of the epidermis overlying
squamous cell carcinoma, with a
localization at the nuclear
envelope.
C: Lamin A (133A2);
homogeneously expressed at the nuclear lamina in the tumor cells.
D: Lamin C (RaLC); expressed in the majority of tumor cells and also showing a localization at the
nuclear envelope.
Original magnification used for photography of images A-D was 20x.
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Figure 4: Lamin
expression in basal
cell carcinoma and the
epidermis overlying
basal cell carcinoma
A: Lamin A (133A2);
homogeneously
expressed in the basal
cell layer of the
epidermis overlying
basal cell carcinoma
and the suprabasal
cells also showing
expression in the
majority of the cells.
B: Lamin C (RaLC);
expressed in the
majority of the cells of
the epidermis overlying
basal cell carcinoma,
and showing
localization at the
nuclear envelope next to localization at the nucleoli.
C: Lamin A (133A2); homogeneously expressed in the tumor cells.
D: Lamin C (RaLC); expressed in the majority of tumor cells but showing a localization at the
nucleoli.
Original magnification used for photography of images A-D was 40x.
Figure 5: Ki-67/lamin A co-expression in normal human skin and basal cell carcinoma (BCC)
A: Lamin A (green) and Ki-67 (red) in normal human skin: Ki-67 positivity is mainly restricted to the
suprabasal cell layers as is the expression of lamin A.
B: Lamin A (green) and Ki-67 (red) in the epidermis overlying basal cell carcinoma: Ki-67 positivity is
enhanced as compared to that in normal human epidermis. Lamin A is homogeneously expressed
in the basal cell layer of the epidermis overlying basal cell carcinoma in contrast to its absence in
basal cells of normal human skin.
C: Co-expression of lamin A (green) and Ki-67 (red) in basal cell carcinoma.
Original magnification used for photography of images A and B was 40x, for image C 20x.
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The mechanism by which the aberrant localization of lamin C in AK and BCC
occurs is still unclear. Nuclear foci of lamin expression have been reported
before in the case of A-type lamins*"^. The authors suggested that these
clustered A-type lamins form deposits from which the lamins will finally be
transported to and assembled in the peripheral nuclear lamina. Aberrant
expression of A-type lamins has furthermore been reported in non-small cell
lung carcinoma^. Cytoplasmic localization of lamin A was observed and
partially explained by the possibility that the lamins were improperly assembled
or even truncated. Deletion of either the lamin A N-terminal domain or the C-
terminal CaaX domain results in the formation of intra-nudear aggregates and
disruption of the endogenous lamins A and C^. Vaughan ef a/, showed that
absence of lamin A from the nuclear envelope correlated with a significant
fraction of lamin C being mis-localized to the nucleolus. Although it thus seemed
likely that lamin A is essential for the localization of lamin C to the nuclear
envelope, the present study shows that the mis-localization of lamin C to the
nucleolus appears to be independent of lamin A. Jagatheesan ef a/.^ found a
speckled pattern of expression for A-type lamins in HeLa cells. These speckles
were found to co-localize with RNA splicing factors and the speckles dispersed
when the cells entered mitosis. The speckled pattern of expression was also
seen by Hozak ef a/.^°, who stated that internal lamins are normally buried in
dense chromatin and are thus inaccessible for antibodies. After removal of the
chromatin, the internal speckly' labeling increases for both lamin A and lamin
A/C antibodies. However, no effect was seen on the labeling of lamin B2, which
remained predominantly located at the peripheral lamina. Furthermore, lamin
foci were found to be associated with sites of DNA replication^. In addition, mis-
localization of lamin C to the nucleolus might be a first step towards its absence
in higher-grade tumors as is suggested in the studies of Venables ef a/.". It is at
least remarkable that the nucleolar localization is restricted to AK and BCC, and
not seen in SCC and normal epidermis.
Regarding simultaneous expression of lamin A an KI-67, our findings
corroborate with previous studies stating that AK possesses more proliferative
capacity than SCC^"^. The differences in proliferation may partially explain
their differential clinical behavior.
In normal tissue A-type lamins are in general restricted to differentiated, non-
proliferative, cells^. In the skin tumors examined, however, we found co-
expression of lamin A and Ki-67 can in approximately 60% of the proliferating
cells. This simultaneous expression was also observed by Janssen ef a/.^ who
showed that a considerable fraction of the Ki-67 positive Reed-Sternberg and
Hodgkin cells expressed also A-type lamins, indicating that those proliferating
cells had a differentiated phenotype. Our recent results in BCC are contrasted
by the findings of Venables ef a/.^, who reported mutually exclusive staining
patterns for lamin A and Ki-67. The major methodological differences between
the two studies were that Venables ef a/.^ used single staining of serial
sections and therefore were unable to demonstrate conclusively that lamin A
was absent from Ki67 positive cells. Furthermore, there seemed to be an
apparent correlation between the absence of lamin C and a low proliferative
index in their series of BCC. This conclusion was also based on staining of
serial sections with the individual antibodies. We feel that the double-staining
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protocol used in the present study may allow a more accurate comparison of
the distribution patterns of Ki-67 and lamin A. We therefore conclude that the
double-stained malignant cells are of a differentiated phenotype but still
possess proliferative capacity.
A sequence of change in lamin expression may characterize basal cell skin
carcinoma. Based upon the findings reported here and those reported
previously " , four stages in the development of BCC might be revealed by
different patterns on A-type lamin expression. Venables ef a/." reported a high
incidence of lamin A negative, Ki-67 positive tumors (stage 1) and suggested
that this group was representative of the origins of the tumor since basal cells
tend to be lamin A negative and Ki-67 positive in normal skin. In this study a
significant group of BCCs were lamin A positive and Ki-67 positive (stage 2).
Up-regulation of lamin A expression in this instance might accompany tumor de-
differentiation. In these tumors a fraction of lamin C was located in the
nucleolus. In Venables studies", lamin C was found in the nucleolus in one
tumor (stage 3) and was completely absent (stage 4) in a number of others. All
of these tumors had a low proliferative index. Since BCC is characterized by
slow growth and an absence of metastasis, this might represent a final phase in
the differentiation process. Thus we propose that tumor progression in BCC is
characterized by absence of lamin A at its origin (stage 1), but as the tumor
progresses lamin A expression is up-regulated (stage 2). During these two
phases tumor cells divide rapidly. As growth slows down, lamin C is first re-
located to the nucleolus (stage 3) and subsequently its expression is largely
diminished (stage 4). Whether these changes in lamin expression influence or
reflect changes in the growth of the tumor is yet to be investigated.
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Abstract
Although the therapeutical role of ajoene, an organosulfur compound of garlic,
in cardiovascular diseases and mycology has been established, its usefulness
in cancer treatment has only recently been suggested. We have applied ajoene
topically to 21 patients with either nodular or superficial basal cell carcinoma
(BCC), resulting in a reduction of tumor size in seventeen patients.
Immunohistochemical assays for Bcl-2 expression in a selection of these
tumors before and after treatment showed a significant decrease of this
apoptosis-suppressing protein. On average, the percentage of tumor cells
expressing the proliferation marker Ki-67 was not decreased, which contradicts
a cytostatic action of ajoene. To obtain further insight into the mode of action of
ajoene, BCC cell line TE354T and short-term primary culture of BCC were
analyzed for apoptosis induction after treatment with the drug. Apoptosis was
detected by morphology of the cells and by flow cytometry. It could be
demonstrated that ajoene induces apoptosis in a dose and time dependent
manner in these cultures.
Taking together the in vivo and in vitro studies, we conclude that ajoene can
reduce BCC tumor size, mainly by inducing the mitochondrion-dependent route
of apoptosis.
Keywords: ajoene, apoptosis, basal cell carcinoma, Bcl-2, cell cycle
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Introduction
Basal cell carcinoma (BCC), a non-melanoma type of skin cancer, is the most
common malignancy in Caucasians. Although generally of indolent nature,
occasionally the tumor can become very aggressive and destructive'. For
treatment of BCC several surgical and non-surgical therapies are available*.
Standard therapies include primary surgical excision, Mohs' micrographic
surgery and cryosurgery. Surgical therapy is preferred in the case of
uncomplicated BCCs . The medical history of the patient, age, tumor
localization and size, physical condition and histological outcome will eventually
determine the therapy choice. Non-surgical treatment schedules become
increasingly important because of better cosmetic result. Non-invasive therapies
like photodynamic therapy (PDT) that uses 5-aminolevulinic acid (5-ALA) as a
photosensitized ^ are still under investigation. Topical application 5-fluorouracil
has also been proven successful in the treatment of BCC^.
One of the approaches by which BCC can be treated is by the induction of
apoptosis in the tumor cells. Our earlier studies do however indicate that a
major fraction of BCC is largely positive for the anti-apoptotic Bcl-2™, thus
suggesting a protection of the tumor cells against programmed cell death.
Drugs that can induce this process in BCC may therefore become important
tools in non-surgical therapy of this widespread disease.
More and more phytochemicals are being applied in cancer prevention and
therapy^. Several epidemiological studies have revealed that garlic consumption
has played a significant role in the reduction of deaths caused by malignant
diseases. The mortality rate among patients with gastric cancer in China was
significantly lower in patients with higher garlic consumption (about 20g/day)
than in patients with lower garlic consumption™. Similar effects were seen in
gastric cancer patients in Italy". Since then, a number of studies have
appeared on the anti-tumor and cytotoxic actions of garlic and its organosulfur
compounds.
Ajoene, an organosulfur compound of garlic, possesses anti-fungal activity^,
inhibits platelet aggregation^, and has been shown to induce apoptosis in
human promyeloleukemic cells^. Furthermore, these authors showed that
ajoene can inhibit the expression of inducible nitric oxide synthase (iNOS), a
major enzyme in the production of nitric oxide (NO) in activated macrophages^.
During inflammatory processes cytokines induce the expression of iNOS in
endothelial cells, followed by high output NO synthesis^' . This NO is thought
to serve as nonspecific immuneprotector^ and can mediate the onset of
apoptosis in a variety of mammalian cells'®. Suschek et al.*° reported that NO
prevents UV-induced apoptosis in the skin and that this NO-mediated protection
tightly correlates with over-expression of the apoptosis-inhibiting component
Bcl-2. Therefore, we studied the expression patterns of the Bcl-2 protein before
and after ajoene treatment of BCC to determine its apoptosis inducing effect.
Since several authors*'^ suggested an effect of ajoene on cell cycle
progression, we furthermore investigated the effect of ajoene on proliferative
activity of the tumor cells by determining Ki-67 expression.
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Materials and Methods
Ajoene
Ajoene [(E)-4,5,9-trithiododeca-1,6,11-triene-9-oxide] was purified from
alcoholic extracts of garlic as described before 23. Briefly, allicin (a diallyl
thiosulfinate that is produced when garlic is crushed) produces ajoene by
incubation of a 2% solution of allicin in acetone/water (3/2) at 80°C for 10h. The
crude product is then purified by column chromatography.
Ajoene treatment in vivo
Twenty-one patients (12 males and 9 females, in age ranging from 49-91 years)
with twenty-five individual histologically proven BCC of nodular (n = 17) or
superficial (n = 8) type with a maximum diameter of 2 cm were selected.
Patients with a suppressed immune system or using immune-suppressive drugs
were excluded. All patients signed an informed consent prior to their inclusion in
the study, which was approved by an Institutional Review Board (Ethics
Committee). Before treatment, the surface area (rnm^) of the lesions was
determined and a biopsy (3mm diameter) of the tumor was taken, fixed in 4%
formaldehyde and embedded in paraffin. The BCCs were then treated by local
application twice a day of a 0.4% ajoene cream (400 mg Ajoene, 0.3 ml
polysorbate 80, and 0.3 ml sorbitonoliate in 100 ml 1 % carbomeric gel)
extending 1 cm beyond the tumor margins. The BCCs were then covered with a
hydrocolloid dressing. The lesions were measured once a month. After
treatment for 6 months, the BCCs were completely removed by surgical
excision, fixed in 4% formaldehyde and embedded in paraffin.
Immunohistochemistry of tissue sections
Paraffin sections (5(.im) were cut onto Superfrost plus slides (MERCK,
Darmstadt, Germany), dried overnight at 56°C, deparaffinized and rehydrated.
Endogenous peroxidase activity was blocked with 0.3% h^CVmethanol and a
microwave antigen-retrieval step was performed. The sections were then
incubated with the primary antibodies Bcl-2 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) or MIB-1 (Immunotech, Marseille, France) both diluted 1:50 in
PBS, followed by incubation with the appropriate secondary antibodies, and
detection via peroxidase with the ABC complex (Vector Laboratories Inc.,
Burlingame, CA, USA). Peroxidase activity was detected using 3,3-
diaminobenzidin (DAB; Sigma-Aldrich Chemie BV, Zwijndrecht, The
Netherlands) as chromogen and the sections were counterstained using
haematoxylin (Fluka AG, Buchs, Germany). After dehydration, the sections
were then embedded using Entellan (MERCK).
The percentage of tumor cells expressing Ki-67 and Bcl-2 was established by
counting a minimum of 500 cells per slide.
BCC cell cultures
The human BCC cell line TE354T (ATCC, Rochville, MD, USA) was cultured in
DMEM (ICN Biomedicals, Cleveland, OH, USA) containing 10% FCS, 1% L-
glutamine and 0,1% gentamycin.
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For primary cultures, BCC tumor tissue was obtained after informed consent,
from patients undergoing Mohs' micrographic surgery, cut into small pieces and
rinsed in calcium- and magnesium-free PBS. Then the tumor pieces were
incubated overnight in DMEM containing 0,125% trypsin and 1% gentamycin at
37°C. After incubation, the trypsinization was blocked by adding an equivalent
amount of fetal calf serum (FCS) and by centrifugation of the solution for 5
minutes at 1200 rpm. The pellet was resuspended in serum-free keratinocyte
medium (GIBCO, Paisley, Scotland, UK) and the washing step was repeated
several times. Then the cells were inoculated in a small flask and put back at
37°C. Medium was refreshed every other day. Fibroblasts were removed at
sub-confluency by adding a solution of 0.125% trypsin and 0.02%EDTA in PBS
for 30-60 seconds at room temperature. Loosened fibroblasts could then be
decanted and the remaining cells were washed several times with medium.
Normal keratinocytes are removed by increasing the calcium concentration from
0.09 mM to 1.6 mM for a period of 5-7 days, after which the normal
keratinocytes should be differentiated and non-proliferative. The remaining BCC
colonies can than be returned to low calcium concentration medium.
Immunohistochemistry of cell cultures
The cell lines were characterized by immunohistochemical detection of several
cytokeratins (CK). CK5 and CK14, detected by mouse monoclonal antibodies
RCK102^ and RCK107^*\ respectively, are the basal cell keratins in
combined and stratified epithelial tissues. CK8, CK18 and CK19 are present in
glandular epithelial structures and carcinomas originating from them, and are
detected by mouse monoclonal antibodies M20 , RCK106^ and RCK108^
respectively. Briefly, the cells were fixed on microscopy cover slides, rinsed in
PBS and incubated overnight with the primary antibody at 4°C. After rinsing with
PBS, the cells were than incubated with the appropriate fluorescent-labeled
secondary antibody at room temperature for 1 hour. After another washing step
with PBS, the slides are mounted in TRIS-glycerol (pH 8.0) containing 0.5
ng/mL 4', 6-diamidin-2-phenylindol-dihydrochloride (DAPI; Sigma-Aldrich
Chemie BV).
Ajoene treatment of cell cultures
Ajoene was dissolved in dimethylsulfoxide (DMSO; MERCK) and further diluted
in the appropriate medium. Ajoene was added to the cells for increasing time
periods (6-24 hours) and in three different concentrations i.e. 1 mM, 5 mM and
10 mM. Final DMSO concentration was less than 0.1% and has been shown not
to interfere with the test results in control studies.
Apoptosis assay
The number of apoptotic cells was quantified using the annexin-V assay *°.
After incubation with ajoene the cells are rinsed several times in PBS and once
in 1ml annexin-binding buffer. The pellet was then resuspended in a solution
containing annexin-V-FITC (1:500) (Nexins Research BV, Hoeven, The
Netherlands) and propidium iodide (PI). Multi-parameter flow cytometry analysis
was used to asses ajoene-induced apoptosis. In early stages of apoptosis,
phosphatidylserine is exposed at the external surface of the cell and can be
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detected by annexin-V. Late apoptotic cells and necrotic cells will also show PI
positivity. Living cells, however will show neither annexin-V, nor PI positivity.
Flow cytometry
Flow cytometric analyses were performed using the FACSort flow cytometer
(Becton Dickinson, Heidelberg, Germany) equipped with a single Argon ion
laser. Fluorochromes were excited at 488nm, and the emission filters used were
515-545 BP (green, FITC) and 600 LP (red, PI). A minimum of 10* cells per
sample was analyzed and data stored in list mode. FITC signals were recorded
as logarithmic amplified data, while the PI signals (DNA content per cell) were
recorded as linear amplified data. For bi-variate FITC/PI analysis no
compensation was used. Forward and side scatter of cells was recovered to
observe morphological changes of cells. All analyses were performed with Cell
Quest software (Becton Dickinson).
Figure 1: Effect of ajoene on BCC
tumor size after topical application
in patients.
BCC located on the forehead
(A,B) and on the abdomen (C,D),
before (A,C) and after (B,D)
topical treatment with ajoene.
Tumor surface areas are as
follows A: 63mm^, B: 42 mrn^, C:
195 mrrrl D: 24 mm*.
Results
To study the effect of ajoene on BCC, 21 patients with in total 25 lesions were
treated by exogenous application of the organosulfur compound. The in vivo
results were verified and extended by in vitro studies on human BCC cell lines.
Effect of ajoene on tumor size, Bcl-2 and Ki-67 expression
Although the patient studies showed heterogeneous results, and
immunohistochemistry indicates that only a subset of the cells is targeted, the
abundance of BCCs showed a positive response to ajoene with respect to size
reduction and decrease of Bcl-2 expression.
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Figure 1 shows the effect of ajoene containing cream on the surface area of
BCCs of two patients after treatment during 6 months. Of the cases examined,
3 tumors showed an increase in tumor size, in 1 tumor no change in size was
noted while in 21 samples tumor size was reduced (Fig. 2). On average, the
size of the BCCs in this study showed a reduction with a median value of 47%
(ranging from 69% increase to 88% decrease) (p < 0.01; Wilcoxon), of which
42% (ranging from 69% increase to 82% decrease) for the nodular type (case
numbers 1, 4-7, 9-15, 17, 19, 21, 23 and 24) and 55% (ranging from 19%
increase to 88% decrease) for the superficial type of BCC (case numbers 2, 3,
8, 16, 18, 20, 22 and 25).
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Figure 2: Effect of ajoene on tumor size after topical application in the individual
samples.
Samples were aligned as follows: 1-3 Tumors of increased size after treatment; 4 Tumor
without change in size; 5-25 Tumors of decreased size after treatment.
Figure 3A shows a selection of 10 cases covering tumors that show either
growth, standstill or regression under influence of ajoene. Figure 3B shows the
percentage of Bcl-2 expressing tumor cells per tumor before and after treatment
with ajoene in this selection. It is obvious that in all cases but one the number of
cells expressing Bcl-2 decreased dramatically i.e. a median reduction value of
47% (ranging from 4% increase to 72% decrease) (p < 0.01; Wilcoxon). For the
nodular type BCC (sample numbers 1, 4, 5, 12, 17 and 21) this approximated
39% (ranging from 4% increase to 72% decrease) and for the superficial type
BCC (sample numbers 2, 3, 22 and 25) 50% (ranging from 33% decrease to
69% decrease).
Figure 3C shows the percentage of Ki-67 expressing tumor cells per sample
before and after treatment. It can be seen that in six cases a decrease in
proliferation index is detected, while in four cases the number of Ki-67 positive
cells was increased. When nodular and superficial type of BCC were analyzed
separately, nodular BCC (sample numbers 1, 4, 5, 12, 17 and 21) showed a
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decrease with the median value of 2% (ranging from 167% increase to 25%
decrease) of Ki-67 positive cells, in contrast to a decrease for the superficial
type of 21% (ranging from 10% increase to 72% decrease) (sample numbers 2,
3, 22 and 25). On average, no significant change was detected for the
percentage of Ki-67 expressing cells before and after ajoene treatment. In fact,
four of the ten (40%) samples examined show an increase of the number of Ki-
67 positive cells after ajoene treatment. This indicates that the effect of ajoene
on cell proliferation is not consistent in BCC.
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Figure 3: Correlation of the effect of
ajoene on tumor size, Bcl-2 and Ki-67
expression in a selection of BCC.
Samples were selected based on their
divergent response to ajoene, i.e. 1-3
Tumors of increased size after treatment;
4 Tumor without change in size;
remaining cases show tumors of
decreased size after treatment. A: BCC
surface area (mm') before and after
ajoene treatment.
B: Percentages of Bcl-2 expression in
BCC tumor cells before and after ajoene
treatment.
C: Percentages of Ki-67 expression in
BCC tumor cells before and after ajoene
treatment.
4 5 12 17 21 22 25
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Figure 4: Bcl-2 (A,B)
and Ki-67 (C,D) staining
in BCC before (A,C)
and after (B,D) ajoene
treatment.
Original magnifications
for images A-B: 40x, for
images C-D: 20x
Figure 4 shows examples of immunohistochemical staining patterns for Bcl-2
(Fig. 4A, B) and Ki-67 (Fig. 4C, D) in BCC, either before (A,C) or after (B,D)
treatment for 6 months with ajoene. Bcl-2 showed a homogeneous staining
pattern before ajoene treatment in contrast to a clearly reduced expression
pattern after topical application of ajoene. For Ki-67, no significant changes in
the number of expressing cells could be detected.
CK expression profile of BCC cell lines
Cells of both TE354T and the short-term BCC c6ll culture showed strong
positive immunoreactivity to the antibodies directed against CK 5 and 14 in the
majority of the cells (results not shown), whereas no reactivity could be detected
for CK18. Positivity for CK8 and CK19 was found in a small fraction of the cells.
This CK-profile is compatible with a BCC origin of the cell cultures 31,32.
Effect of ajoene on apoptosis in BCC cell cultures
To further investigate the underlying mechanism of the (potentially) growth
inhibitory effect of ajoene in vivo, we used BCC cell cultures for more advanced
apoptosis assays. The results of the annexin-V assay are depicted in Figure 5.
It can clearly be seen that the apoptosis induction in BCC cell culture, either
commercially available or derived from short-term cell culture, is both dose- and
time-dependent. It can be noted that BCC cells from short-term culture are
more susceptible for apoptosis induction by Ajoene than the commercially
available BCC cell line, a phenomenon that may be related to a higher growth
rate noted for the short-term culture. Furthermore, 10mM Ajoene seems to
have an almost optimal effect on apoptosis induction, especially after 24 hours.
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Figure 5: The effect of incubation with ajoene on cell viability in TE354T cell line (A-C)
and short-term culture of basal cell carcinoma (D-F). The fraction of living cells is
depicted as squares, the fraction of apoptotic cells is depicted as dots.
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Discussion
Several therapies for the treatment of BCC exist*. In general, surgical excision
is the therapy of first choice, but it may be obvious that a non-invasive treatment
is preferred. Here we show for the first time that ajoene, a sulfur-containing
compound of garlic, is effective in the treatment of BCC. The present study also
aimed at elucidating the underlying biological effect of this phytochemical. We
showed that 84% of the tumors, treated with an ajoene-containing cream were
significantly reduced in size after 6 months of treatment. It was shown that the
superficial tumors showed a larger reduction in size next to a larger reduction in
the number of cells expressing Bcl-2, as compared to the nodular tumors, which
may be explained by the fact that the ajoene cream can more easily penetrate
the superficial tumors. A similar differential effect on tumor size reduction was
previously seen in case of treatment of BCC with PDT. Complete initial
clearance of more than 90% for superficial lesions was seen in contrast to 10-
64% for nodular BCC^**. Another possible topical treatment for BCC is
imiquimod. Imiquimod is an immune response modifier that has been
demonstrated to induce cytokines such as interferon-alpha, interferon-gamma
and interleukin 12 that promote an immune response in the tumor cel ls^^.
However, in the majority (92%) of BCC patients treated with imiquimod, local
reactions were seen at the tumor site including erythema, itching, crusting and
even severe erosion^. This is in contrast to our study using ajoene where no
significant side effects were observed.
When comparing the Ki-67 immunostaining results before and after topical
application of ajoene to BCC in patients, no reproducible shift in the percentage
of Ki-67 positive cells was noted. BCCs showing an increased proliferative cell
fraction were seen next to tumors with a decreased proliferative activity.
Therefore we can conclude that in BCC patients the anti-tumorigenic effect of
ajoene is not only explained by a cytostatic effect of the drug.
Tumor size reduction may therefore be better explained by the apoptosis-
inducing ability of ajoene. To test this hypothesis we have applied an assay to
directly prove a diminished protection against apoptosis, rather than procedures
to detect apoptotic cells in BCC, such as the TUNEL assay"*®. The latter protocol
normally also detects necrotic cells and is therefore non-specific, which can
explain the divergent results in the literature, showing between 0.6% and 51%
of apparently apoptotic cells in BCC^"*\ The Annexin V-assay 30 or the M30
Cytodeath assay * cannot be used in case of tissue sections of BCC.
Furthermore, the real apoptotic fraction is rapidly cleared from the tumor by
phagocytosis. Immunohistochemical staining of the tumors treated with ajoene
revealed a decreased number of cells expressing Bcl-2. This provides a
possible mechanism for the effect of ajoene on BCC. By reducing the number of
Bcl-2 positive, apoptosis-resistant, tumor cells, ajoene may increase the
susceptibility for apoptosis in the tumor cells, which will eventually result in a
reduction of tumor size.
This finding is furthermore supported by the observation that, when added to
the culture medium of BCC cells, ajoene induces apoptosis in these cells. This
apoptosis-inducing effect is both time and dose dependent. Taken together,
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these findings provide an important step in dissolving the underlying molecular
mechanisms of the anti-tumor action of ajoene.
Recently Dirsch et al.*^ and Ahmed et al .^ proved that ajoene induces
apoptosis in leukemic cell lines by triggering the mitochondria-dependent
caspase cascade. The authors furthermore reported that Bcl-2 expression was
significantly decreased in these cells'*'' and that over-expression of Bcl-x(L), an
apoptosis-regulating protein, clearly diminished the ajoene-induced caspase-
activation as well as apoptosis"''. Kwon et al."^ reported that diallyl disulfide
(DADS), another component of garlic, induces apoptosis of human leukemia
HL-60 cells in a concentration- and time-dependent manner.
We conclude that ajoene can have a diminishing effect on the growth of BCC by
influencing the disturbed balance between proliferation and apoptosis. Our
earlier studies showed that on average 6% of the tumor cells in BCC show both
an increased proliferative activity as well as a reduced apoptotic susceptibility^.
It is most likely that this progressive cell population is the most sensitive target
for ajoene treatment.
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Summary
Basal Cell Carcinoma (BCC) is a non-melanoma type of skin cancer that
accounts for almost 80% of all skin malignancies and is the most common
malignancy among Caucasians. Since apoptosis and proliferation are two
important processes to be considered when studying growth characteristics of
tumor, this thesis mainly concentrates on the (dis)balance between these two
phenomena in BCC.
In the first chapter the molecular cell biology of BCC is being reviewed. Clinical
features and the risk factors are discussed. Next to the obvious environmental
risk factors such as exposure to sunlight and toxic agents, there are a number
of genetically determined factors. Several syndromes exist, like Xeroderma
Pigmentosum and Nevoid Basal Cell Carcinoma Syndrome, that may lead to a
higher susceptibility for the development of BCC. Also immuno-suppression
seems to play a major part in predisposing for the development of skin cancer.
A subject of major interest is the origin of the tumor. There are several
arguments for an inter-follicular epidermal origin, but most evidence points
towards an origin from the hair follicle, and more specifically, the stem cells of
the follicle, located in the bulge area.
Therefore, in the second chapter the human hair follicle is studied
immunohistochemically, using the stem cell marker cytokeratin 19 and the
apoptosis-suppressing protein Bcl-2, to detect the localization of the stem cells.
It seems that indeed two areas exist that may provide these cells. When the
BCCs are studied for the expression pattern of Bcl-2 (chapter 3.1), we see that
the tumors express this apoptosis-regulating protein homogeneously.
Remarkably however, the apparently normal epidermis overlying BCC also
shows an enhanced expression of Bcl-2, in contrast with a strict basal cell
localization in the healthy epidermis. This suggests that superficial tumors may
arise from the basal cells, whereas the nodular and morphea type may originate
from the hair follicles, and may explain why both epidermis and hair follicle
show comparable patterns of expression for some proteins such as cytokeratins
and cell adhesion molecules. This is also found in the study using other Bcl-2
like proteins (chapter 3.2), where BCCs show a basal cell-like phenotype and
the overlying epidermis again shows an intermediate expression pattern
between normal epidermis and BCC. Whether this phenomenon is induced by
factors originating from BCC or can be regarded as a first step in skin
carcinogenesis remains to be established.
In chapter 4 the differential expression patterns of nuclear lamins, which are
related to differentiation and proliferation, are shown in different stages of skin
cancer. Significant changes occur in the expression patterns of A-type lamins in
both pre-malignant and malignant lesions of the skin. The profound overlap of
staining patterns of lamin A and the proliferation marker Ki-67 indicates that the
proliferating tumor cells may obtain a certain degree of differentiation. Also,
lamin A expression in the basal cell layer of the apparently normal epidermis
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overlying BCC again suggests its involvement in the primary process.
Furthermore, a sequence of four stages in the development of BCC is revealed
by different patterns of A-type lamin expression. Stage 1 is represented by a
high incidence of lamin A negative, Ki-67 positive tumors. As the tumor
progresses to stage 2, lamin A expression is upregulated. During these two first
stages the tumor shows a high degree of proliferation. When growth slows
down in stage 3, lamin C expression is first relocated to the nucleoli and
subsequently its expression is largely diminished during stage 4, the stage at
which the cells obtain their final BCC phenotype.
In chapter 5 a possible new treatment for BCC is introduced by applying
ajoene, an organosulfur compound of garlic, directly to the tumors. The in vivo
studies showed a clear diminishing effect on tumor size in most cases and
suggested selective induction of apoptosis by down-regulating the expression of
the anti-apoptotic Bcl-2 protein. These findings were furthermore supported by
in vitro studies, showing that ajoene can induce apoptosis in both a BCC cell
line and a short-term primary culture of BCC. A major advantage of this
treatment is that ajoene showed no side effects in normal skin. This study
provides a good basis to further investigate apoptosis-inducing agents for their
future application in BCC treatment.
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Samenvatting
Het basaalcelcarcinoom (BCC) is een niet-melanoma type huidkanker dat
ongeveer 80% van alle maligne huidaandoeningen uitmaakt. Het is de meest
voorkomende maligniteit in mensen van het Caucasische ras. Aangezien
apoptose en proliferatie twee belangrijke processen zijn die in acht genomen
moeten worden wanneer men groeikarakteristieken van een tumor onderzoekt,
concentreert deze thesis zieh met name op de (verstoorde) balans tussen deze
twee fenomenen in BCC.
In Hoofdstuk 1 werd de moleculaire celbiologie van BCC besproken. Klinische
kenmerken en risico-factoren worden besproken. Naast de overduidelijke
omgevingsfactoren zoals blootsltelling aan zonlicht en gifstoffen, zijn er ook een
aantal genetische factoren. Er bestaan verschillende syndromen, zoals
bijvoorbeeld Xeroderma Pigmentosum en Nevoid Basaal Cel Carcinoma
Syndroom, die aanleiding geven tot een hogere gevoeligheid voor de
ontwikkeling van BCC. Daarnaast speelt immuunsuppressie ook een grote rol.
Een onderwerp van grote belangstelling is het ontstaan van een BCC. Er zijn
verschillende argumenten die duiden op een oorsprong in de interfolliculaire
epidermis, echter de meeste bewijzen duiden op een oorsprong in de
haarfollikels, en meer specifiek, de stamcellen van de follikel, gelocaliseerd in
het zogenaamde 'bulge' gebied.
Daarom werd in Hoofdstuk 2 de menselijke haarfollikel onderworpen aan een
immunohistochemische analyse, gebruik makend van de stameel merker
cytokeratine 19 en het apoptose-onderdrukkende Bcl-2 eiwit, om de localisatie
van de stamcellen te determineren. Er blijken inderdaad twee gebieden
aanwezig te zijn die mogelijk stamcellen leveren. Wanneer BCCs
immunohistochemisch bestudeerd worden voor de expressie van het Bcl-2 eiwit
(Hoofdstuk 3.1), zien we dat de tumoren dit apoptose-regulerend eiwit
homogeen tot expressie brengen. Opmerkelijk is echter, dat de schijnbaar
normale epidermis boven de tumor ook een verhoogde expressie van het Bcl-2
eiwit vertoont, in tegenstelling tot wat we zien een gezonde huid, waar het Bcl-2
eiwit enkel in de basal laag tot expressie komt. Deze bevindingen suggereren
dat de superfaciele tumoren ontstaan van de interfolliculaire epidermis, en dat
de nodulaire en sprieterige types ontstaan uit de haarfollikels, en verklaren
tevens waarom zowel epidermis als haarfollikels vergelijkbare expressie
patronen van eiwitten zoals de cytokeratines en cel-adhesie moleculen
vertonen. Dit werd ook geconstateerd in een Studie naar Bcl-2-gerelateerde
eiwitten in BCC (Hoofdstuk 3.2), waar BCCs een fenotype vertonen
gelijkaardig aan de basale cellen, en de overliggende epidermis opnieuw een
expressie patroon vertoont dat tussen dat van gezonde huid en BCC ligt. De
vraag of dit fenomeen wordt geinduceerd door factoren die afkomstig zijn van
het BCC of dat dit gezien kan worden als een eerste stap in het ontstaan van
huidkanker blijft voorlopig nog onbeantwoord.
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In Hoofdstuk 4 werden de differentiele expressie patronen van de nucleaire
lamines, eiwitten gerelateerd aan proliferatie en differentiatie, besproken in de
verschwende stadia van huidkanker. Significante veranderingen treden op in de
expressie patronen van de A-type lamines in zowel pre-maligne als maligne
huidaandoeningen. De overduidelijke simultane expressie van lamine A en de
proliferatie merker Ki-67 duidt op het feit dat de prolifererende tumor cellen
beschikken over een zekere graad van differentiatie. Verder duidt de
aanwezigheid van lamine A in de basale laag van de schijnbaar normale
overliggende epidermis op een betrokkenheid van deze cellaag in het primaire
proces. Op basis van de differentiele expressie patronen van lamin A kunnen er
vier stadia onderscheiden worden in de ontwikkeling van een BCC. Het eerste
stadium wordt gekenmerkt door de aanwezigheid van lamine A negatieve, Ki-67
positieve tumoren. Progressie naar stadium 2 gaat gepaard met op-regulatie
van de expressie van lamine A. Gedurende deze twee eerste stadia vertonen
de tumoren een hoge proliferatie index. Wanneer de proliferatie afneemt in het
derde stadium, wordt lamine C herlocaliseerd naar de nucleoli alvorens
gedurende stadium 4 te verdwijnen; dit is het stadium waar de cellen hun
uitendelijke BCC fenotype aannemen.
In Hoofdstuk 5 werd een mogelijke nieuwe behandeling voor BCC
geintroduceert, door een directe applicatie van ajoene, een bestanddeel van
knoflook. De in vivo studies vertonen een duidelijke reductie in tumor afmeting
in het merendeel van de bestudeerde patienten en sugereren een selectieve
inductie van apoptosis door vermindering van de expressie van het apotose-
onderdrukkende eiwit BCI-2. De resultaten werden bevestigd door in vitro
studies waaruit is gebleken dat ajoene apoptose kan induceren in zowel een
korte-termijn kweek van BCC als een commercieel verkrijgbare BCC cellijn. Een
groot voordeel van deze behandeling is dat ajoene geen bijwerkingen vertoont
in de normale huid. De Studie levert een geode basis voor de verder Studie naar
apoptose-inducerende reagentie en hun toekomstige toepassing in behandeling
van BCC.
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Dankwoord
'Hoe moet ik hier nu aan beginnen?', dat vroeg ik me af toen ik aan mijn
dankwoord wilde beginnen. Het dankwoord, de tekst die als laatst geschreven
wordt, maar waarschijnlijk als eerst gelezen. Bij de ontvangst van proefschriften
zie je altijd iedereen direct doorbladeren naar de laatste bladzijden, om te kijken
wie er al dan niet vermeid wordt in het dankwoord. Ik moet toegeven, dat deed
ik ook altijd. Als tweede waren dan de Stellingen aan de beurt. Eigenlijk is dat
toch wel schandalig, de stukken die het minst met het onderzoek te maken
hebben worden als eerste grondig bestudeerd en door sommigen hevig
bekritiseerd. Wat weten zij daar nu van? Velen van nun weten niet welke zware
taken het zijn om dezetekstjes te produceren. Waarschijnlijk beseffen ze niet dat
hier meer bloed, zweet, tränen en slapeloze nachten aan vooraf zijn gegaan
dan voor de rest van het 'boekje'. De (soms) prachtig geTllustreerde verhalen
die het grootste deel van het boek uitmaken, zijn immers op voorhand al
uitbundig besproken met de nodige co-auteurs en de AIO wordt als het ware
aan het handje geleid naar het einde. Maar dan, het dankwoord, de grote test
voor iedere schrijver, nu komt het enkel en alleen op de AIO zelf aan. En 'wee je
gebeente' als je iemand vergeten bent.
Ja ja, ik ben het aan het uitstellen, ik probeer er een beetje omheen te schrijven
om het penibele moment maar uit te stellen. Ik heb nachten lang gedacht over
een originele manier om mijn dankwoord neer te schrijven, maar de ideeen die
ik kreeg waren slechts zwakke kopieen van de andere 'originelen'. Ik heb er
zelfs over gedacht om het dankwoord gewoon helemaal weg te laten. Weg met
de traditie, tijd voor vernieuwing! Maar er zijn toch wel een aantal mensen die
mij gedurende de afgelopen jaren 'gestuurd en gesteund' hebben. Ik kan bijna
niet anders dan hun namen hier even vermelden, met het risico dat ik anderen
dan weer vergeet.
Bij de mensen die ik zeker wil bedanken hoort natuurlijk op de eerste plaats
mijn vader, Bert Tilli. Pap, als tweeling en waterman hebben we al menige
discussies gevoerd, maar hoe dan ook, je bent me, samen mat mama, altijd
blijven steunen in alles wat ik deed. Als ik weer eens te lang achter elkaar zat te
studeren, wisten jullie me telkens weer even af te leiden met een leuk dagje in
Antwerpen of een gezellig etentje, dan kon ik er altijd weer even tegen. Bedankt
voor alles, en ik hoop dat je er nu ook gerust in bent, het boekje is klaar!
Wat mensen op het werk betreft, zijn er ook de nodige namen die ik moet
vermelden. Allereerst natuurlijk mijn promotoren Prof.Dr. Neumann en Prof.Dr.
Ramaekers, zonder hun was mijn boekje nooit geworden wat het nu is, de
dermatoloog en de celbioloog, niet altijd met elkaar eens, maar uiteindelijk een
goede symbiose. Bedankt!
Dr. Gertruud Krekels, niet van het begin al co-promotor, maar wel altijd al
betrokken bij het onderzoek. Gertruud, bedankt voor alles. Zeker na het vertrek
van Prof. Neumann was jij een steun en mijn link met de kliniek.
114
Monique Ummelen en Wendy Dignef verdienen zeker ook een plaatsje in dit
dankwoord. Met jullie heb ik de nodige jaren samen doorgebracht op kamertje
5.214. Het was er niet ruim, met zijn drieen, soms met zijn vieren, maar het was
er wel altijd gezellig. Ik heb een leuke tijd gehad en zal er altijd met plezier aan
terug denken. Ik ben heel blij dat jullie mijn paranimfen willen zijn.
Wat de rest van de crew bij MCB betreft, ook zij hebben hun steentje
bijgedragen aan de gezelligheid en stonden altijd paraat als er eender welk
probleem was. Bedankt MCB!
Angela Stavast (meisje Kooij) en Jaqueline Braun, de 'Gho-girls', samen
hebben we veel plezier beleefd, zowel op het werk als daarbuiten. Ik wil jullie
bedanken voor alle goede raad en de enorme steun in moeilijke tijden.
Anneloes, Sander, Stijn, An, Lieven, Jürgen, Sofie, Gaby, Steven, Eric-Jan,
Sandra, bedankt allemaal voor jullie interesse in mijn onderzoek.
Mijn schoonouders wil ik graag bedanken voor het feit dat ik hun eetkamer drie
maanden lang als bureau heb mögen gebruiken.
Als laatste, maar daarom niet minder belangrijk, wil ik Jan Van Geet bedanken.
Lieve 'grote smurf, ook jij bent een enorme steun geweest tijdens een groot
deel van mijn AlO-schap. Jij, als geen ander, zag vaak de vertwijfeling als het
weer eens tegen zat op het werk. Jij moest mijn frustraties voortdurend
aanhoren en jij hebt mij telkens weer moed ingesproken als ik het niet meer zag
zitten. Ik had het zeer zeker niet zonder jou gekund en ik ben er trots op dat ik
me tegenwoordig jouw vrouw mag noemen.
Bedankt!
Claudia
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werkte zij van januari 1998 tot mei 1998 aan haar thesis, getiteld 'De rol van
apoptose en proliferatie bij het ontstaan van het basaal eel carcinoom', bij de
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Latin (botanical) name: /\///um saf/Vum
Common names: Garlic. Poor Man's Treacle
Garlic Soup (The French Kitchen, Harris & Warde)
4tbsp olive oil
5 whole garlic bulbs
25g flour
1.51 hot water
4 sprigs of thyme
sea salt
freshly ground black pepper
100g thin vermicelli
large bunch parsley
Heat the oven to 140°C
Drizzle the oil over a rastin trayand put cut garlic bulbs on it, roast 1-1 5 hours until
soft and golden. Remove garlic from oven and sqeeze out the soft butterly flesh
Put it in a saucepan with juices from roasting tray and mash with a spoon Over a
medium heat, mix in the flour so it absorbs the oil and makes a roux Slowly
pour in the hot water, stirring constantly. Add thyme and seasoning and simmer for
20 minutes. Remove from heat, discard thyme sprigs and use a blender to make
the soup smooth. Return to the heat, add vermicelli and cook for 3 minutes
Add parsley just before serving.
